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Role of the Microbiome in Maintaining Host 
Health 
At all stages of life, humans are associated with microorgan-
isms and their products. Humans coevolved with microbes in the 
environment, and each body habitat has a unique set of micro-
organisms in its microbiota (1). The microbiome (term coined by 
Joshua Lederberg) consists of the ecological community of com-
mensal, symbiotic, and pathogenic microorganisms that share our 
body (2). The host organism together with its microbiome consti-
tutes the “holobiont” (Greek, holos, whole/entire), and the totality 
of the genome is the “hologenome” (3, 4). Changes in the holobi-
ont may impact the complex signaling network, thereby influenc-
ing the hologenome leading to health or disease. 
The human body is estimated to be composed of 3 × 1013 eu-
karyotic cells and 3.9 × 1013 colonizing microorganisms, such that 
host cells and microbiota are of nearly the same number in an in-
dividual (5). The largest concentrations of microbes occupy the 
gut, skin, and oral cavity. The microbiota of our system is well tol-
erated by our immune system due to the coevolution of these mi-
croorganisms over time. The overwhelming majority of gut mi-
crobiota are Eubacteria. The collective genome, or metagenome, 
of the enteric microbiota contains over 100 times the number of 
genes in the human genome, and there are approximately 10-fold 
more genes in each of our microbiomes than in each of us, en-
coding the greatest source of potential antigens with which the 
immune system must cope (6). The microbiome in humans signif-
icantly enriches the metabolism of glycans, amino acids, and xe-
nobiotics. It is also responsible for the synthesis of vitamins, iso-
prenoids, and other nutrients, making humans “superorganisms” 
whose metabolism represents an amalgamation of microbial and 
human attributes (7). 
Each individual emits a distinct and personalized cloud of mi-
croorganisms into his or her surroundings (8). The microbiome in 
humans is also not constant during lifespan, but rather changes 
with age. Culture and location also have a profound impact on 
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Abstract 
Humans consider themselves discrete autonomous organisms, but recent research is rapidly strengthening the appreciation that associated 
microorganisms make essential contributions to human health and well being. Each person is inhabited and also surrounded by his/her own 
signature microbial cloud. A low diversity of microorganisms is associated with a plethora of diseases, including allergy, diabetes, obesity, ar-
thritis, inflammatory bowel diseases, and even neuropsychiatric disorders. Thus, an interaction of microorganisms with the host immune sys-
tem is required for a healthy body. Exposure to microorganisms from the moment we are born and appropriate microbiome assembly dur-
ing childhood are essential for establishing an active immune system necessary to prevent disease later in life. Exposure to microorganisms 
educates the immune system, induces adaptive immunity, and initiates memory B and T cells that are essential to combat various patho-
gens. The correct microbial-based education of immune cells may be critical in preventing the development of autoimmune diseases and 
cancer. This review provides a broad overview of the importance of the host microbiome and accumulating knowledge of how it regulates 
and maintains a healthy human system.   
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the microbiome (9). Health status is yet another factor influenc-
ing the microbiome compositional status. In one study, the growth 
dynamics of gut microbiota in health and disease have been in-
ferred from a single metagenomic sample (10). These authors copy 
the number and ratio at origin and terminus to detect the actively 
growing species in a microbiome. In this way, they showed dif-
ferences between virulent and avirulent strains, population diur-
nal oscillations, and bacterial species predominant during disease 
and diet changes. 
Diet is a particularly important factor in determining the mi-
crobiota composition of the gut (11). Thus, vegans, vegetarians, 
and omnivores have distinct microbiomes. Total counts of Bacte-
roides spp., Bifidobacterium spp., Escherichia coli (E. coli), and En-
terobacteriaceae spp. were significantly lower in vegan samples 
than in controls. In contrast, total counts of Klebsiella spp., Entero-
bacter spp., other Enterobacteriaceae, Enterococcus spp., Lactoba-
cillus spp., Citrobacter spp., and Clostridium spp. were similar in 
people with different diets. Subjects on a vegetarian diet ranked 
between vegans and omnivores. The total microbial count did not 
differ between the dietary groups (12). Notably, the microbiome of 
a person can be altered rapidly by changes in dietary patterns. It 
has been demonstrated by David and colleagues (13) that short-
term consumption of diets composed entirely of animal or plant 
products can alter the microbial community structure. An animal-
based diet increased the abundance of bile-tolerant microorgan-
isms, including Alistipes, Bilophila, and Bacteroides and decreased 
the levels of Firmicutes that metabolize dietary plant polysaccha-
rides (Roseburia spp, Eubacterium rectale, and Ruminococcus bro-
mii). Thus, the gut microbiome rapidly responds to diet. 
Microbiome Taxonomy and Its Future 
The taxonomy of microbiomes reflects their complexity and the 
challenges encountered in their understanding. Microbiomes in-
clude species across all major kingdoms, including viruses as well 
as Archaea, bacteria, and microbial eukaryotes. Our current depth 
of knowledge is associated with different methods of investiga-
tion, targeted surveys, and scope of studies conducted. To date, 
the most comprehensively investigated phylogenic group in health 
and disease has been bacteria. 
Prokaryotes 
List of Prokaryotic Names with Standing in Nomenclature 
(http://www.bacterio.net) includes two prokaryotic domains (or 
empires), subdivided into 30 phyla in the domain Bacteria and 5 
phyla in the domain Archaea. Together, these 35 phyla encompass 
about 2,400 genera and 12,400 species (14). This list is based on 
strict requirements, including the availability of reference strains, 
and does not include all available reference strains deposited 
in culture collections, including the ones for which genome se-
quences are already available (15–17). The addition of whole-ge-
nome phylogenetic analysis allows a refined positioning in the 
phylogenetic hierarchy as new tools are being developed (18–21). 
This approach brings some conflicts with the current classification, 
as has happened when the 16S rRNA gene phylogenetic classifi-
cation competed with the phenotypic classification (22–24). In ad-
dition, the ability to target and obtain the sequence of the genes 
used for phylogenetic classification (16S rRNA, recA, rpoB, gyrB, 
etc.) using culture-independent methods also adds to the known 
diversity. Specialized curated databases that allow the propaga-
tion of this knowledge include SILVA, Ribosomal Database Project, 
and the Human Oral Microbiome Database (23, 25, 26). This cul-
ture-independent approach raised to 46 the number of phyla (23). 
How much of this diversity is in the human microbiome is unclear. 
However, it is already clear that organisms known to be environ-
mental are also associated with health and that at least 30 pro-
karyotic phyla and 950 genera are associated with the human mi-
crobiome (27, 28). 
Microbial eukaryotes 
The microbial eukaryotes are extremely diverse and do not fit 
under a single keyword. Although accurate, the eukaryotic super-
groups defined by phylogenomics [Opisthokonta, Amoebozoa, 
Excavata, Archaeplastida, and SAR (Stramenopiles + Alveolates + 
Rhizaria)] are unfortunately uninformative compared with previous 
classification methods used in the literature. From the clinician to 
the lay person, terms such as fungi, protists, parasites, protozoa, 
and amoebae are much more familiar. In this area, current knowl-
edge is based mostly on their roles as causative agents of disease; 
few studies have focused on healthy individuals or within a defined 
illness in a restricted number of individuals (29–33). Until recently, 
the focus on single disease agents also meant neglecting the re-
mainder of the eukaryotic microbiome (34, 35). 
The human eukaryotic microbiome includes pathogens, com-
mensals, and beneficial organisms. The fungi (Opisthokonta) har-
bor a wide diversity of organisms, with an overlap for the skin 
with the local environment (35). The fungi include the Ascomycota 
(Candida albicans), Basidiomycota (Cryptococcus neoformans), Mi-
crosporida (Encephalitozoon intestinalis), and Zygomycota (Rhizo-
pus microsporus). As fungi are part of the environment and human 
alimentation, it may be difficult to differentiate between transient 
and commensal organisms without a longitudinal study, unless a 
disease or an opportunistic infection occurs (36, 37). The Acantho-
cephala, most closely related to the rotifers, include Macracantho-
rhynchus hirudinaceus. The helminths (Opisthokonta), which are 
classified as part of the animals, include the cestodes (tapeworms, 
Taenia saginata), trematodes (flukes, Schistosoma mansoni), and 
nematodes (roundworms, Enterobius vermicularis). Although the 
majority of the helminths cause illness in millions of people world-
wide, a few helminth species have been used in therapy (38, 39). 
The protozoa include the Amoebozoa (Amoebozoa; amoeba: Ent-
amoeba histolytica), Metamonada (Excavata; flagellates: Giardia in-
testinalis), Parabasilia (Excavata; Dientamoeba fragilis), Ciliophora 
(SAR; ciliates: Ballentidium coli), Apicomplexa (SAR; Cryptosporid-
ium parvum), and Stramenopile (SAR; Blastocystis hominis). These 
protozoa are all medically important even though not all carriers 
are symptomatic (30, 35). The Archaeplastida (including green and 
red algae) can be present in the microbiome of the skin and diges-
tive tract. Additional sequences available through the sequencing 
of targeted genes, including via metagenomics, have expanded 
this knowledge and are maintained and curated in databases such 
as SILVA (23). A current view of the tree of life, encompassing the 
total diversity represented by sequenced genomes, was published 
recently by Hug and colleagues (40). 
Viruses 
The gut microbiome includes bacteriophages that influence the 
bacterial hosts. The bacteriophage in the human gut are of three 
classes: a set of core bacteriophages shared among more than half 
of the human population, a common set of bacteriophages found 
in 20% to 50% of individuals, and a set of bacteriophages that are 
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unique to a person. Healthy gut phageome (aggregate of bacte-
riophage in the gut) is significantly decreased in individuals with 
gastrointestinal diseases (41). The International Committee on Tax-
onomy of Viruses in its 2014 release listed 104 families, 505 gen-
era, and 3,186 species of all known viruses (42). The human virome 
overlaps with other animal viromes. These dsDNA, ssDNA, dsRNA, 
ssRNA– ssRNA+ viruses, and dsDNA and ssRNA retroviruses can 
affect any of the tissues within the body. Human protists (nonfun-
gal microbial eukaryotes) have their own viral challenges, which 
are being uncovered within the human virome (43). Much more 
is known about mycoviruses and their intracellular transmission 
during cell division and sporogenesis, and it is recognized that 
their life cycles generally lack an extracellular phase. Most known 
mycoviruses have dsRNA genome, but an increasing number of 
positive- or negative-strand ssRNA and ssDNA viruses have been 
isolated and characterized (44). Most of the archaeal viruses have 
been isolated from members of the Euryarchaeota and Crenar-
chaeota with broader morphologic characteristics than their bac-
terial counterpart (45). Little is known of the impact of archaeal 
viruses on the human virome. The dsDNA, ssDNA, dsRNA, and ss-
RNA bacteriophages have a great impact on prokaryotic ecology 
through their ability to modify population structure. A list of vi-
ral pathogens is maintained by the ViPR resource, whereas pro-
phages are available at PHAST (46, 47). 
Future of taxonomy 
An open challenge in taxonomy is to refine the classifications 
to be more compatible with the emerging methods of molecular 
biosurveillance and detection, requiring targets associated to an 
outcome or being able to identify strains at multiple body-sites 
across the domains of life (21, 48). This work is dependent on a 
greater understanding of the true diversity in the population with 
the direct sequencing of large sample sets and/or large cohorts, 
such as the Human Microbiome Project, MetaHIT, BioMarks, and 
future large-scale projects (49–51). New resources are now at-
tempting to bridge the different approaches and topics of detec-
tion across domains, such as the Human Pan-Microbe Commu-
nity database (34). The ability to isolate and sequence single cells 
offers the opportunity to deepen both our understanding of the 
genomic composition of taxonomic diversity, as well to put this 
diversity in context of its environment, microbial partners, bioge-
ography, and host physiologic status both at the local and sys-
temic levels (52–54). 
Beyond this time, taxonomy and the species level classification 
focused on vertical transmission of conserved information to de-
scendant cells. The strain definition is associated with gene com-
position and gene modification, including mutations and antigenic 
variation following homologous DNA recombination, CRISPR sys-
tem (clustered regularly interspaced short palindromic repeats), 
gene transfer, mobile elements, epigenetics, etc. Moving from 
targeted gene phylogeny to whole-genome comparison has its 
own limitations that can be complemented by the inclusion of 
other omics as once metabolic panels, protein, and DNA finger-
printing profiles were used. This polyphasic analysis allows un-
derstanding genetic relatedness and phylogenic relationship in 
the context of disease, reservoir, niche transmission within a sin-
gle individual, propagation within a population, and dissemina-
tion among environments. An increasing number of gene trans-
fer events among domains is being documented as well as across 
ecological niches (55–57). The genetic modification can be due 
to increases in genetic content, but genetic loss also has critical 
consequences in competitiveness or niche settlement (58, 59). As 
no clear general phylogenetic definition of strain has emerged in 
this era of genomics, efforts are to differentiate the different iso-
lates with markers not yet found in other genomes and/or SNP 
(20, 21, 60, 61). 
The Infant Microbiome and Transgeneration 
Effects 
Until recently, the placenta was considered a “sterile” intrauter-
ine environment. Aagaard and colleagues (62) reported that the 
placental microbiome is consistently different from other parts 
of the body, including the skin and urogenital tract. Interestingly, 
the placental microbiome is most similar to that of the oral cav-
ity. Thus, these authors suggested that microbes travel to the pla-
centa from the mouth via blood. The results reinforce data that 
have suggested a link between periodontal disease in the mother 
and the risk of preterm birth. 
Infant-associated microbial communities initially possess high 
concentrations of facultative anaerobes, such as E. coli and Strep-
tococcus spp., but these populations are replaced by strict anaer-
obes coinciding with a reduction in oxygen tension (63–65). In ad-
dition to environmental routes of inoculation, the specific mode by 
which the infant is delivered is now known to influence the early 
gut microbiome structure and trajectory. 
Although there is emerging evidence that the fetus encounters 
placental and amniotic bacteria in utero, it is clear that parturition 
contributes to the infant’s first major inoculation of colonizing mi-
crobes (63, 66, 67). Microbial communities colonize external sur-
faces of the infant immediately following birth. This includes var-
ious microbial populations that are established and maintained 
along the gastrointestinal tract. The percentage of babies deliv-
ered through cesarean section (C-section) has risen in many coun-
tries. Although a number of C-section deliveries are performed 
for obstetrical indications, a large proportion is not medically in-
dicated and may be due to maternal request and may incur sev-
eral risks for the child (68). Obstetricians in many medical settings 
are paid more for cesarean delivery, and it is well known that pri-
vate hospitals and practitioners encourage cesarean delivery (69). 
However, recent studies demonstrated that babies born vaginally 
are healthier compared with babies born by cesarean delivery. As 
such, infants delivered vaginally tend to harbor microbiotas that 
are typically encountered in the female reproductive tract, such 
as Lactobacillus. In contrast, cesarean delivery is typically associ-
ated with Staphylococcus spp. and other bacteria that are associ-
ated with the mother’s skin and hospital environment (65, 70, 71). 
Children delivered by C-section have significantly increased risk 
of asthma, systemic connective tissue disorders, juvenile arthritis, 
inflammatory bowel disease, immune deficiencies, leukemia (72), 
and Crohn disease (73). Although there are some indications that 
infants born via C-section may be more susceptible to colonization 
by Clostridium difficile (C. difficile) or methicillin-resistant Staph-
ylococcus aureus (S. aureus), and may be at an increased risk for 
pathologies later in life (71, 72), additional mechanistic studies are 
required to conclude causal relationships in this regard. 
The infant microbiome exhibits several shared attributes re-
gardless of birth method. In general, the infant microbiome is 
often dominated by the genera Bifidobacterium, Bacteroidetes, 
and members of clostridial taxa (74). In the seminal 2012 study 
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conducted by Yatsunenko and colleagues (9), gut microbiomes 
were characterized from individuals located in three distinct geo-
graphic locations (i.e., United States, rural Malawi, and rural Ven-
ezuela). Regardless of the host’s location, microbial populations 
converge toward an adult community by 3 years of age (9). Fur-
thermore, microbial community diversity increased as the host 
aged across all populations (9). Infant microbiomes exhibit hall-
marks of functional redundancy, in that interindividual taxonomic 
variation is common despite sharing a stable and uniform met-
abolic potential (75). This functional redundancy during neona-
tal development may contribute to metabolic, digestive, and im-
mune system homeostasis (74, 76). During infancy, the impact of 
alterations in community assembly on function has been linked 
to outcomes such as malnourishment, C. difficile–associated di-
arrhea, and necrotizing enterocolitis (74, 76, 77). Early-life micro-
biome disruption may potentially increase risk for developing ce-
liac disease, asthma, type I diabetes, and obesity (70, 72, 78–81). 
These conditions could have long-term medical implications that 
interact reciprocally with the gut microbiome. 
Perturbations or durable disruptions of the infant microbiome 
may proceed via several paths, with hospitalization and antibiotic 
use considered to be primary causes. Preterm and term infants 
who are hospitalized early in life are at a greater risk for nosoco-
mial C. difficile infection (74, 82). Thus, the hospital environment 
is a reservoir for infectious agents that may be deleterious for at-
risk populations, such as preterm infants with underdeveloped 
immunologic function. As antibiotics select for resistant and resil-
ient strains, indiscriminant usage of antimicrobials may drive gut 
dysbiosis in certain instances. Several studies have characterized 
the influence of antibiotic usage on restricting gut microbiota di-
versity, potentially increasing susceptibility to aggressive bacte-
rial infections like C. difficile and vancomycin-resistant Enterococ-
cus bacteremia (82–84). 
As it does in adults, diet exerts a strong influence on the struc-
tural composition of infant-hosted microbiomes. Culture-depen-
dent and independent studies indicate that breastfed infants often 
possess a significantly different and less diverse gut microbiome 
relative to formula-fed infants (9, 64, 85–87). Accordingly, human 
milk incorporates several bioactive compounds important for in-
fant nutrition, including lipids, proteins, and lactose. In addition, 
several milk molecules enhance immunologic and neurologic de-
velopment (88–90). Escaping digestion by host glycosyl hydrolases, 
soluble milk glycans are transferred to the distal colon, where they 
are exposed to the gut microbiota of the infant. Thus, these human 
milk oligosaccharides (HMO) are available to guide the establish-
ment and function of the infant microbiome. HMOs are hetero-
geneous carbohydrate polymers that are the third most abundant 
milk component at several grams per liter (91). HMO structures in-
corporate the monosaccharides d-glucose, d-galactose, N-acetyl-
glucosamine, l-fucose, and N-acetylneuraminic acid, with more 
than 200 unique HMO isomers composed of these components 
identified to date (91, 92). 
Breastfeeding infants often display a microbiome enriched for 
commensal Bifidobacteria that can utilize HMOs. Bifidobacteria 
are Gram-positive anaerobes of the phylum Actinobacteria, which 
typically colonize infants and adults to a lesser degree (93–95). 
Accordingly, Bifidobacterium longum (B. longum) subsp. infantis 
is a major commensal of breastfed infants, with this lineage pos-
sessing a large genomic cluster that enables HMO utilization (95). 
That unique gene assemblage permits the catabolism of specific 
small mass HMOs that other Bifidobacteria cannot process. For 
example, in comparison with other Bifidobacteria, B. longum 
subsp. infantis flourishes in the presence of milk that contains 
α1,2-fucosylated HMOs (96). An individual’s complement of HMO 
structures is somewhat dependent on the mother’s genotype and 
may vary by gestational age and stage of lactation. The relative 
concentrations of α1,2-linked fucosyl moieties depend on the fu-
cosyltransferase 2 allele (96). Women with a functional copy of 
this gene, termed secretors, may confer certain health benefits to 
their infant such as a decreased risk for diarrheal diseases (96–98). 
HMOs can decrease the presence of gastrointestinal pathogens 
using two primary mechanisms. HMOs themselves mimic patho-
gen-binding sites of receptors that decorate the surface of host 
cells (99–101). Studies have documented this effect using Vibrio 
cholerae, Streptococcus pnemoniae, and E. coli (102–104). In ad-
dition, high levels of Bifidobacteria are correlated with lower in-
cidence of potentially dangerous neonatal infections, potentially 
due to competitive exclusion (105, 106). Gut microbiota develop-
ment during infancy can have long-lasting effects on the individ-
ual’s future health. Colonization of fucosyllactose-utilizing Bifido-
bacteria is due to an ABC transporter that acts as a key genetic 
factor for fucosyllactose utilization (107). 
Human milk is generally accepted as the best nutrition for new-
borns and has been shown to support the optimal growth and de-
velopment of infants (108). Human milk also provides bioactive 
components that are important to optimize gut microbial colo-
nization, immune maturation, metabolic development, and even 
cognitive development. Breast milk has a low buffering capac-
ity, which would make the gut more susceptible to a lowering of 
pH due to acid production from bacterial fermentation in the co-
lon. The fecal pH of the breastfed infant is between 5 and 6 dom-
inated by Bifidobacteria, whereas formula-fed infants have a fecal 
pH in the range of 8 to 9. The acetic acid in the gut of breast-
fed infants is frequently present as an acetate buffer. This effect 
was not observed in formula-fed infants. The lower pH in the gut 
is an important factor in restricting the growth of Enterobacte-
ria, Clostridia, and the Bacteroides and favors the proliferation 
of the acid-tolerant Bifidobacteria and Lactobacilli (109). Human 
milk also contains many antimicrobial factors, such as partially 
digested or fermented peptides, milk-borne fatty acids, human 
lactoferrin, lysozyme, and secretory IgA. These factors may de-
crease the prevalence of pathogens in the gut’s ecosystem in in-
fants. The broad range of nondigestible oligosaccharides specifi-
cally found in human milk but not in other mammals’ milk (108) is 
a major factor in the prevention of pathogen growth in the gas-
trointestinal tract. Stunted infants fed poorly have low amounts of 
sialylated HMOs in the gut. These oligosaccharides are not used 
by the body, but rather used by the gut microbes. Charbonneau 
and colleagues (110) colonized germ-free mice with a consor-
tium of bacterial strains cultured from the fecal microbiota of a 
6-month-old stunted infant and fed recipient animals with nor-
mal diet with or without purified sialylated bovine milk oligosac-
charides (S-BMO). S-BMO produced a microbiota-dependent body 
weight gain, indicating growth promotion in the presence of gut 
microbiota. However, control animals that were germ free did not 
increase body weight, demonstrating some bacteria in the gut are 
involved in weight gain. 
Infant formula is often based on bovine milk unless it is plant 
derived. Fluid dairy milk contains oligosaccharides with a simi-
lar structure to HMOs, which may suggest similar functionality 
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despite being incorporated at relatively low concentrations (108, 
111–113). At the moment, there are efforts to supplement infant 
formula with oligosaccharides, although HMO structures are dif-
ficult to synthesize and may not be commercially viable (114). 
However, oligosaccharides from other sources may increase bifi-
dobacterial concentration as a preferred endpoint, including ga-
lacto-oligosaccharides and fructo-oligosaccharides. 
Use of oral probiotics by the mother during pregnancy is 
thought to help the developing baby. Microbes in the placenta or 
amniotic fluid affect fetal innate immune gene expression during 
late pregnancy. Maternal probiotic supplementation significantly 
modulated the expression of Toll-like receptor (TLR)- related genes 
both in the placenta and in the fetal gut. Thus, fetal and placental 
immune physiology may be modulated by maternal dietary inter-
ventions, including using specific probiotics (115, 116). It has also 
been shown that maternal probiotic supplementation during preg-
nancy and breastfeeding reduces the risk of eczema in the infant 
(116). Probiotic supplements continue to impact infants in their 
early years. It has been shown that infant formula supplemented 
with the probiotics Lactobacillus rhamnosus (L. rhamnosus) GG and 
Bifidobacterium lactis Bb-12 offers a safe means of reducing the 
risk of early acute otitis media and antibiotic use and the risk of re-
current respiratory infections during the first year of life (117). Pro-
biotics enhance gut-specific IgA responses, which are frequently 
defective in children with food allergy (118). Kainonen and col-
leagues (119) have demonstrated that exclusive breastfeeding pro-
motes an anti-inflammatory cytokine milieu, which is maintained 
throughout infancy. Such an immunologic environment limits hy-
perresponsiveness and promotes tolerization, thereby prohibiting 
the onset of allergic disease. 
Infantile colic (excessive crying) is a common problem in about 
20% of healthy thriving infants in the first 3 months of life (120). 
The risk factors associated with the development of infantile colic 
include maternal smoking, increased maternal age, and firstborn 
status. Infantile colic could also be related to cow’s-milk protein 
allergy and atopy (121). Several studies have demonstrated that 
administration of probiotics containing Lactobacillus reuteri (L. re-
uteri) DSM 17938 significantly improved colic symptoms by reduc-
ing crying and fussing times in breastfed infants with colic (122, 
123). Treatment of colic with L. reuteri did not affect the global 
composition of the microbiota. The decrease in colicky symptoms 
was linked to changes in the microbiota, with a relative increased 
abundance of the phyla Bacteroidetes and genus Bacteroides af-
ter treatment with L. reuteri (124). 
Microbiome and Aging 
As humans age, the composition of the microbiome also 
changes (9). Aging is accompanied by the onset of a myriad of 
clinical changes, including a basal proinflammatory state (“in-
flamm-aging”) that directly interfaces with the microbiota of older 
adults and enhances their susceptibility to diseases that accom-
pany aging. Studies in older adults demonstrate that the gut mi-
crobiota correlates with diet, basal level of inflammation, and lo-
cation of residence (e.g., community dwelling, long-term care 
settings; refs. 125–127). Links between the microbiota and a va-
riety of clinical problems plaguing older adults have been made, 
including physical frailty, C. difficile, colitis, vulvovaginal atrophy, 
colorectal carcinoma, and atherosclerotic disease (128). 
The most drastic change associated with the aging gut is a 
change in the relative proportion of organisms, for example, Fir-
micutes dominate in the young and Bacteroidetes in the elderly. 
Reduction in the diversity of bacteria comprising subpopulations 
is seen in individuals with high frailty, although living in a commu-
nity undermines this alteration (125, 129). 
Aging-associated oxidative stress induces aggressive poten-
tial and virulence factors of anaerobic bacteria, thereby causing 
morphologic alterations of bacterial cells that could impact the 
host. The microbiota may also influence host gene expression by 
regulating miRNAs (130). Analysis of the network functions re-
vealed that differentially regulated miRNAs between infants and 
adults and miRNAs that decreased during aging shared two net-
work functions: inflammatory disease and inflammatory response. 
miRNAs promote aging by modulating their targets to drive cell 
senescence and aging in different tissues or organs. There is sig-
nificant variation in the expression of miRNA during aging. Ge-
nome-wide assessment of miRNA expression revealed that the 
majority of miRNAs decreased with age (131, 132). Interestingly, 
host-derived miRNAs may also influence the composition of the 
gut microbiome (133). 
It has been documented that calorie restriction can increase the 
life span of model organisms (134). Notably, Zhang and colleagues 
(135) demonstrated that calorie restriction enriches bacterial phy-
lotypes positively correlated with lifespan. Bacteria of the genus 
Lactobacillus have been shown to increase in animals on low-fat 
diet, and this environment reduces phylotypes that are negatively 
correlated with lifespan. Caloric restriction– induced changes in 
the gut microbiota occur concomitantly with a significant reduc-
tion in serum levels of lipopolysaccharide (LPS)-binding protein, 
suggesting that animals undergoing calorie restriction establish a 
structurally balanced architecture of gut microbiota that exerts a 
health benefit through the reduction of antigen load from the gut. 
Strikingly, dietary changes can detectibly influence host environ-
ment in as little as 24 hours, with longer term changes correlating 
with novel enterotype clustering in the host (136). 
Multiple studies in centenarians indicate extreme aging is 
characterized by microbial changes deemed unique from other 
age groups, with emphasis placed on organismal composition 
and increased inflammatory effects (137, 138). Fecal sampling 
by Rampelli and colleagues (138) revealed a distinctive func-
tional profile with a decrease in short-chain fatty acid (SCFA) 
production and saccharolytic potential but an increase in pro-
teolytic potential. A total of 116 microbial genes were found to 
be correlated with aging, including those essential to the me-
tabolism of tryptophan, phenylalanine, tyrosine, valine, and ly-
sine. Implications of such variability include changes in well be-
ing, aging, and disease susceptibility. This was accompanied by 
an increase in the occurrence of pathobionts, bacteria usually 
present in low numbers in adults. Proinflammatory effects of 
the pathobionts are exaggerated by a decrease in Faecalibac-
terium prausnitzii (F. prausnitzii), a species associated with anti-
inflammatory influences (137). 
The relationship between aging and the microbiome is not 
strictly one-sided; it has been demonstrated that host aging can 
actually be impacted by interspecies communication. Animal fe-
cundity, development time, and lifespan were all dependent on the 
amount and type of bacteria they were fed. There are multiple lines 
of evidence demonstrating the ability of microbes to substantially 
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change host physiology, as it pertains to these parameters (139). 
Accordingly, manipulating the microbiome of older adults holds 
promise as an innovative strategy to positively influence the de-
velopment of comorbidities associated with aging (128). 
Rozsa and colleagues (140) recently proposed the “microbiome 
mutiny hypothesis,” whereby some microorganisms of the micro-
biome could switch to higher virulence (microbiome mutiny) in 
old or seriously ill people, to optimize their transmission under 
the conditions of increased background mortality. This proposed 
virulence shift might contribute to the death of old or seriously ill 
people even in the absence of apparent disease. 
In the central nervous system (CNS), polyphenols present in 
many edible plants exert anti-inflammatory effects (141) and 
act on the brain in several ways. Like antioxidant vitamins, di-
etary polyphenols contribute to the regulation of oxidative stress 
and improve vascular health. Notably, intestinal microbiotas con-
vert dietary polyphenols to phenolic acids, stimulating the pro-
liferation of Bifidobacteria and decreasing the ratio of Firmicutes 
to Bacteroidetes, relative to controls. Polyphenols also stimulate 
SCFA production by bacteria (142). Wang and colleagues (143) re-
cently reported that the microbiome can convert grape-derived 
polyphenol to the phenolic acids, 3-hydroxybenzoic acid and 
3-(3ʹ-hydroxyphenyl)propionic acid, which interfere with the as-
sembly of β-amyloid peptides into neurotoxic β-amyloid aggre-
gates that play key roles in the pathogenesis of Alzheimer disease. 
Thus, in the brain and other tissues, many healthful effects of poly-
phenols may relate to their conversion to various metabolic deriv-
atives by the gut microbiome while aging. 
Microorganisms and Immune Function 
Through coevolution with their hosts, microbes exert a major 
influence in shaping the development of the immune system, put-
ting it under selective pressure to develop the capability to dis-
cern between invasive pathogens that it is imperative to control 
and commensal resident microbes that are beneficial to tolerate 
(144, 145). Many developmental aspects of the adaptive immune 
system are influenced by the composition of bacterial colonization 
of the gut. Thus, the mammalian immune system, which is tasked 
with the duty of controlling microorganisms, is in turn fundamen-
tally shaped by microorganisms (146). For example, it has been 
demonstrated that changes to the symbiotic microbiota early in 
life, or the absence of it, can lead to exacerbated type II immu-
nity and allergies due to aberrant immune functionality. The mi-
crobiota is a strong inducer of proinflammatory Th17 cells and 
regulatory T cells (Treg) in the intestine. The microbiota-induced 
Tregs express the nuclear hormone receptor RORγt and differ-
entiate along a pathway that also leads to Th17 cells. In the ab-
sence of RORγt+ Tregs, Th2-driven defense against helminths is 
more efficient, whereas Th2-associated pathology is exacerbated. 
Thus, the microbiota regulate type II responses through the in-
duction of type III RORγt+ Tregs and Th17 cells, thereby balanc-
ing immune responses at mucosal surfaces (147). Exercise can also 
influence the immune system and how they modulate microor-
ganisms (148, 149). Intense exercise causes immunosuppression, 
whereas moderate-intensity exercise improves immune function 
and potentially reduces risk and severity of respiratory viral infec-
tion by increasing stress hormones, reduce excessive local inflam-
mation, and skew the immune response to a Th2 phenotype (148). 
Similarly, exercise can also influence bacterial infections. Pape and 
colleagues (150) demonstrated a reduction of bacterial infection 
in people with physical activity compared with those that main-
tain a sedentary lifestyle. 
Similar to adaptive immunity, the innate immunity is also influ-
enced by the microbiome. One example of this is neutrophil aging. 
Aged neutrophils exhibit impaired migration and reduced proin-
flammatory properties. Microbiota influence neutrophil aging via 
TLR- and MyD88-mediated signaling pathways. Depletion of the 
microbiota significantly reduces circulating numbers of aged neu-
trophils and improves pathogenesis and inflammation-related or-
gan damage in models of sickle cell disease or endotoxin- induced 
septic shock. Thus, host microbiota may play a role in regulating a 
disease-promoting neutrophil subset that promotes tissue injury 
in various inflammatory diseases (151). 
Although active immunity is essential to combat infection, in-
adequate control over immune responsiveness due to the inability 
to establish immune tolerance can also have dire consequences, 
regardless of whether the response is directed against a foreign 
pathogen or self. Meanwhile, one of the major benefits of immune 
tolerance is the ability to maintain a commensal microbiome con-
sisting of a multitude of foreign microorganisms. Thus, the mech-
anisms for establishing tolerance are a vital aspect of the immu-
noregulatory framework. One crucial element in instructing the 
immune system to be self-tolerant is the education of thymus T 
cells during development. In the thymus, self-reactive cells are 
either eliminated or differentiated into tolerogenic Foxp3+ Tregs 
(152). Apart from the thymus, the immune system is also educated 
in the gut, where it has been shown that the interaction of T cells 
with commensal microbiota results in the peripheral generation of 
Tregs rather than pathogenic effector cells. Failure of this tolero-
genic process can lead to the development of autoimmune dis-
eases, including colitis (152). 
Microorganisms Encountered Early in Life 
Prevent Autoimmunity and Allergy 
The human microbiome is important for human health, be-
havior, and disease, yet its function and dynamics during healthy 
and disease states are not fully understood (153). It is also not 
fully understood how the microbiome interacts with the host im-
munity thereby preventing autoimmunity. The hygiene hypothe-
sis first put forward by Strachan (154) postulates that the lack of 
early exposure to microorganisms (either beneficial or pathogenic) 
would lead to poor development of the immune system. The lead-
ing idea is that some microorganisms that coevolved with us are 
able to protect against a large spectrum of immune-related dis-
orders (155). Although the hygiene hypothesis is not universally 
applicable, it offers some explanative power to interpret the ef-
fects of microorganism exposure in early life on preventing auto-
immunity and allergy. 
Children growing up on dairy farms are protected from al-
lergy, hay fever, and asthma (156, 157). Asthma is a chronic in-
flammatory disease triggered by acute inflammation of the bron-
chial tube, leading to production of extra mucus. This can make 
breathing difficult and trigger coughing, wheezing, and shortness 
of breath. The number of asthma cases is increasing all over the 
world, but the causes remain obscure. It has been hypothesized 
that increased cleanliness, reduced family size, and subsequent 
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decreased microbial exposure could explain the increases in global 
asthma prevalence (158). Evidence from bronchial brushings im-
plicates phyla present in healthy individuals with variation pres-
ent in disease conditions such as cystic fibrosis, chronic obstruc-
tive airways disease, and asthma. The microbiome can exacerbate 
the phenotypes seen in the condition, as well as explain the vari-
ability in phenotypes observed (159). Many cytokines and chemo-
kines are involved in the pathophysiology of asthma. Th2 cytokines 
may play an important role in the pathophysiology of asthma. The 
Th1 cells secrete IL2 and IFNγ, whereas the cytokines, IL4, IL5, IL9, 
and IL13 are derived from Th2 cells, although they may also be 
derived from other cell types. The distinction between Th1 and 
Th2 cells is not as distinct in humans as in mice (160, 161). Ac-
cording to the hygiene hypothesis, the lack of infection and ex-
posure to environmental endotoxins may alter the balance be-
tween Th1 and Th2 cells. 
Although children on farms are much less likely to get 
asthma, the underpinnings of protection are not clearly under-
stood. Early-life contact with livestock and their fodder and con-
sumption of unprocessed cow’s milk have been identified as the 
most effective protective exposures. Studies of the immunobiol-
ogy of farm living point to activation and modulation of innate 
and adaptive immune responses by intense microbial exposures 
(162). Schuijs and colleagues (157) demonstrated that chronic ex-
posure to low-dose endotoxin or farm dust protects mice from 
developing house dust mite (HDM)-induced asthma. Endotoxin 
reduced epithelial cell cytokines that activate dendritic cells (DC), 
thus suppressing type II immunity to HDM. Loss of the ubiqui-
tin-modifying enzyme A20 in lung epithelium abolished the pro-
tective effect. An SNP in the gene encoding A20 has been as-
sociated with allergy and asthma risk in children growing up on 
farms. Thus, the farming environment protects from allergy by 
modifying the communication between barrier epithelial cells 
and DCs through A20 induction. 
From delivery, the microbiome assembly might influence 
asthma. Babies born via C-section, who experience an altered tra-
jectory of microbiome assembly, are more prone to asthma than 
those born vaginally. Similarly, children treated with antibiotics are 
also more prone to asthma attack (163). Lif Holgerson and col-
leagues (164) analyzed the oral biofilm in healthy 3-month-old in-
fants born by C-section or delivered vaginally. Among more than 
300 bacterial taxa analyzed, Slackia exigua was detected only in in-
fants delivered by C-section. Furthermore, significantly more bac-
terial taxa were detected in the infants delivered vaginally (79 spe-
cies/species clusters) compared with infants delivered by C-section 
(54 species/species clusters). Overall, the vaginally delivered in-
fants had a higher number of bacterial taxa. A higher prevalence 
of salivary Streptococcus salivarius, Lactobacillus curvata, Lactoba-
cillus salivarius (L. salivarius), and Lactobacillus casei (L. casei) was 
detected in infants delivered vaginally (165). 
A longitudinal human study by Arrieta and colleagues (166) 
reported that infants at risk of asthma have transient gut micro-
bial dysbiosis during the first 100 days of life. The authors col-
lected stool and urine samples from more than 300 babies at 3 
months and 1 year, as well as information on their health at 1, 3, 
and 5 years. Then, they analyzed levels of gut microbes in each 
stool sample. Babies that had low or undetectable levels of four 
bacteria, Lachnospira, Veillonella, Faecalibacterium, and Rothia, at 
3 months all went on to show early signs of asthma, wheezing 
and skin allergies, at 1 year. The babies that did not develop these 
symptoms invariably had high levels of the four microbes in their 
3-month stool samples. The authors also used the stool samples 
from the asthma-prone 3 month olds to colonize the guts of mice 
that had been raised in a bacteria-free environment. The animals 
developed inflamed lungs indicative of asthma. However, upon 
inoculating the four missing microbes to the digestive tracts of 
these mice along with the feces, they no longer had a heightened 
risk of developing asthma. The studies demonstrated that certain 
bacterial species that are encountered early in life could train the 
immune system to prevent asthma. 
Microbial dysbiosis in early life can alter the trajectory of im-
mune development and provide the setting for allergic disorders 
in later life (167). Dysbiosis may trigger autoimmune diseases via 
inappropriate posttranslational modification of host proteins (168). 
Endogenous and microbial enzymes have the capacity of intestinal 
enzymatic neoantigen generation by posttranslational modifica-
tion of host proteins. The hygiene hypothesis stipulates that mi-
crobial exposure during early life induces immunologic tolerance 
via immune stimulation and hence reduces the risk of allergy de-
velopment. Several common lifestyle factors and household prac-
tices, such as dishwashing methods, may increase microbial expo-
sure. Hesselmar and colleagues (169) investigated whether lifestyle 
factors are associated with allergy prevalence. The authors dem-
onstrated that in families that used hand dishwashing, allergic dis-
eases in children are less common than in children from families 
who use machine dishwashing. The authors were of the opinion 
that a less efficient dishwashing method may induce immune tol-
erance via increased microbial exposure. 
Autoimmunity is more prevalent in the population of some 
northern European countries, such as Finland and Estonia, when 
compared with Russia. It was found that Bacteroides species are 
less abundant in Russians but dominate in Finnish and Esto-
nian infants. Their LPS exposures arose primarily from Bacteroi-
des rather than from E. coli, which is a potent innate immune ac-
tivator. The Bacteroides LPS was found to be structurally distinct 
from E. coli LPS and inhibits innate immune signaling and endo-
toxin tolerance. It was observed that unlike LPS from E. coli, Bac-
teroides dorei LPS does not decrease incidence of autoimmune 
diabetes in nonobese diabetic mice. Early colonization by im-
munologically silencing microbiota may thus preclude aspects 
of immune education (170). 
Rheumatoid arthritis (RA) is an autoimmune disease in which 
the immune system attacks the joints, leading to swollen and pain-
ful joints. The mucosal surfaces are sites of rheumatoid arthri-
tis initiation. The common occurrence of periodontal dysbiosis in 
rheumatoid arthritis suggests that oral pathogens may trigger the 
production of disease-specific autoantibodies and arthritis in sus-
ceptible individuals. Periodontitis is characterized by the presence 
of citrullinated autoantigens that are primary immune targets in 
rheumatoid arthritis. The citrullinome in periodontitis is similar to 
the hypercitrullination observed in the rheumatoid joint, implicat-
ing this mucosal site in rheumatoid arthritis pathogenesis. Recent 
studies identified the periodontal pathogen Aggregatibacter ac-
tinomycetemcomitans (A. actinomycetemcomitans) as a bacterial 
trigger of autoimmunity in rheumatoid arthritis by inducing hy-
percitrullination in host neutrophils. The pore-forming toxin leu-
kotoxin A secreted by A. actinomycetemcomitans triggers autoan-
tigen citrullination in the rheumatoid arthritis joint (171). Zhang 
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and colleagues (172) reported alterations in the gut, dental, or sa-
liva microbiome that distinguished patients with rheumatoid ar-
thritis from healthy controls. Individuals with rheumatoid arthritis 
had low numbers of Haemophilus spp., whereas L. salivarius was 
very high in these patients. It has been reported in experiments in 
mice that inoculation with Bifidobacterium adolescentis (B. adoles-
centis) exacerbated autoimmune arthritis. B. adolescentis is known 
to induce Th17 cells in the intestine (173). Interestingly, the fre-
quencies of Th17 cells and levels of IL17 strongly correlated with 
systemic disease activity at both the onset and the progression of 
rheumatoid arthritis (174). 
Role of Microbiome in Obesity 
Obesity results from an imbalance of food intake, basal metab-
olism, digestive tract microbial composition, and energy expen-
diture (175, 176). According to Turnbaugh and colleagues (177), 
the gut microbiome should be considered as a set of genetic fac-
tors that together with host genotype and lifestyle contribute to 
the pathophysiology of obesity. It is observed that the intestinal 
bacteria in obese humans and mice differ from those in lean indi-
viduals. Obese mice microbiota was found to be rich in Firmicutes 
compared with the lean mice microbiota, which was abundant 
in Bacteroidetes (177). Strikingly, colonization of germ-free mice 
with microbiota from obese mice was sufficient to cause a sig-
nificant increase in total body fat, as compared with colonization 
with microbiota from lean mice (177). The obese microbiome has 
an increased capacity to harvest energy from the diet, thereby in-
creasing weight gain in the host (177, 178). Colonization of adult 
germ-free mice with a gut microbial community harvested from 
conventionally raised mice increased body fat within 10 to 14 days, 
despite an associated decrease in food consumption. This change 
involves several linked mechanisms: microbial fermentation of di-
etary polysaccharides that cannot be digested by the host; sub-
sequent intestinal absorption of monosaccharides and SCFA; their 
conversion to more complex lipids in the liver; and microbial reg-
ulation of host genes that promote deposition of the lipids in ad-
ipocytes (179). 
Transfer of human microbiota to mice can phenocopy such 
effects, as shown by Ridaura and colleagues (180). Cohabitation 
of mice harboring an obese microbiota with mice containing the 
lean microbiota prevented the development of increased body 
mass and obesity-associated metabolic phenotypes in obese cage 
mates. Rescue correlated with invasion of specific members of Bac-
teroidetes from the lean microbiota into obese microbiota and was 
diet dependent. The study confirmed that specific bacteria along 
with diet could induce obesity. 
Childhood obesity is considered one of the most serious global 
health issues in our society. Obese children are more likely to be 
obese in adulthood and are at greater risk of premature death 
and adverse health outcomes in later life (181). Administration of 
three or more courses of antibiotics before children reach age 2 
years is associated with an increased risk of early childhood obe-
sity (182). When given early in life, antibiotics that disrupt micro-
biota composition, and consequently the metabolic activity of the 
microbiota, can affect the body mass of the host by either promot-
ing weight gain or stunting growth (183). The correlation of anti-
biotics to obesity has been earlier shown in animal models (184). 
Food is broken up into components that tend beneficial micro-
organisms. Bacterial fermentation of a diet rich in fibers leads to 
the production of SCFA, which as noted above includes acetate, 
propionate, and butyrate in the gut (185, 186). Interestingly, butyr-
ate promotes colonic health and helps prevent cancer (185, 187, 
188). The consumption of high fat and high calorie foods nega-
tively impacts the beneficial microbes, which are believed in turn 
to promote obesity. Notably, obese people have lower Bacteroide-
tes and more Firmicutes in their distal gut than lean subjects, and 
the introduction of low fat and carbohydrate diets increased the 
proportion of Bacteroidetes (175, 189). 
Obesity is also known to impair cognition and produces at-
rophy of brain regions associated with learning and memory. In 
animal studies, it has been shown that, even before the onset of 
diabetes or metabolic syndrome, early-stage obesity produced 
deficits on cognitive tasks that require the prefrontal cortex. Im-
paired cognition was associated with synapse loss, including re-
duced numbers of dendritic spines and expression of synaptic pro-
teins, as well as structural alterations in the microglia. Thus, obesity 
must be considered as a contributing factor to brain dysfunction 
mediated through the gut–brain axis (190, 191). 
It has been demonstrated recently that some bacterial spe-
cies are beneficial to the host by preventing obesity. In animal 
models and humans, the abundance of Akkermansia muciniphila 
(A. muciniphila) is decreased in obese and type II diabetic mice 
(192), and use of the bacterium as a probiotic is beneficial to the 
host. Interestingly, whole bacterium is not essential to prevent 
obesity. Intake of the membrane protein of the bacterium per se 
could be beneficial to the host. Amuc_1100, a specific protein 
isolated from the outer membrane of A. muciniphila, interacts 
with TLR2, is stable at temperatures used for pasteurization, im-
proves the gut barrier, and recapitulates the beneficial effects of 
the bacterium (193). 
Metformin is a well-established drug in the management of 
type II diabetes and obesity. Recent studies suggest that the mi-
croorganisms are involved in mediating the beneficial effects of 
metformin on glucose metabolism. Metformin shifts gut microbi-
ota composition through the enrichment of mucin-degrading A. 
muciniphila as well as several SCFA-producing microbiota, includ-
ing Butyrivibrio, Bifidobacterium bifidum, Megasphaera, and Pre-
votella (194). Overall, there is substantial evidence of the key role 
of microbiota in obesity and its adverse effects. 
Microbiome and Cardiovascular Diseases 
The gut microbes produce a large range of metabolites that 
act not only in the gut, but also systemically, and this large pool 
of known and unknown metabolites is not fully understood (195). 
The metabolite trimethylamine N-oxide (TMAO) is the first poten-
tially direct link between the gut microbiota and atherosclerotic 
heart disease. Trimethylamine is produced by the gut microbiota 
from nutrients containing l-carnitine, choline, and phosphatidyl-
choline and is subsequently oxidized by hepatic flavin-containing 
monooxygenases to TMAO. TMAO has been proposed to inter-
fere with cholesterol transportation, and TMAO precursors pro-
mote foam cell formation and atherosclerosis in animal models, 
but not in the presence of antibiotics to the drinking water, sug-
gesting a microbiota-dependent mechanism (195). 
Hypertension is a risk factor for coronary heart disease, yet 
whether gut microbiota dysbiosis is involved in the development 
of hypertension remains largely unknown. In a recent study, it was 
observed that the bacterial genus Prevotella and Klebsiella were 
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overrepresented in individuals with hypertension. Fecal transplan-
tation from hypertensive human donors to germ-free mice in-
creased blood pressure in animals, thereby demonstrating the di-
rect influence of gut microbiota on high blood pressure (196). 
Beneficial microorganisms are known to protect against ath-
erosclerosis. The lack of gut microbiota in germ-free apolipopro-
tein E (ApoE)-null mice, an experimental model of human athero-
sclerosis, was found to induce the development of atherosclerotic 
plaques even when animals were fed a standard low-cholesterol 
diet. Colonization with normal human microbiota prevented ath-
erogenesis in germ-free ApoE-null mice fed a standard low-cho-
lesterol diet but not a diet with high-cholesterol content (197). 
The bacterial genera Eubacteria, Anaeroplasma, Roseburia, Oscil-
lospira, and Dehalobacteria appeared to be protective against ath-
erosclerosis and showed significant negative correlation with ath-
erosclerotic plaque size and plasma adipocyte fatty acid binding 
protein and cholesterol (198). A. muciniphila is also beneficial to 
the heart. The bacteria attenuate atherosclerotic lesions by ame-
liorating metabolic endotoxemia-induced inflammation through 
restoration of the gut barrier (199). 
Microbiome and Behavior 
The exponential growth in our collective knowledge of the hu-
man microbiome has seen the study of gut microorganisms move 
beyond the traditional preserve of strictly microbiological disci-
plines. As our appreciation of the structure and dynamics of the 
gut microbiome has flourished, so too has our grasp of the im-
plications for host physiology in health and disease. Perhaps one 
of the more surprising aspects of this host–microbe dialogue is 
the complex interactions that manifest as alterations in brain and 
behavior. Moreover, the bidirectional nature of this conversation 
needs to be considered in the context that disruptions to CNS 
function can be expressed distally as alterations in microbiome 
composition and function in the gastrointestinal tract. These as-
pects of host–microbe dialogue are generally important to med-
icine, due to the impact of behavioral states that widely impact 
and/or reflect the operation and progression of pathogenic pro-
cesses and their treatment (e.g., the negative impact of depres-
sion on general therapeutic compliance). 
These complex reciprocal interactions are facilitated by the mi-
crobiome–gut–brain axis, which incorporates the gut microbiome 
as a critical node of the communication network encompassing 
the CNS, the neuroendocrine and neuroimmune systems, the sym-
pathetic and parasympathetic arms of the autonomic nervous sys-
tem, and the enteric nervous system (200). The focus on the gut 
microbiome has proved to be a surprisingly fertile ground, and 
the evidence garnered from a variety of preclinical approaches has 
converged to illuminate how the gut microbiome regulates multi-
ple behaviors, physiologic readouts, and indeed many fundamen-
tal aspects of brain function. 
In this regard, surveys of microbiota-deficient germ-free ani-
mals have proved particularly informative. The use of these ani-
mals in general is not new, but their application to CNS-directed 
queries has been a notable feature of recent research efforts (201, 
202). From a behavioral perspective, these animals display a less 
anxious phenotype (203–206), and this atypical performance can 
be normalized if the animals are colonized postweaning (205). Re-
markably, it has also been demonstrated using both the germ-free 
paradigm and an antibiotic-induced microbiota deficiency that 
anxiety-like behaviors can be transferred via the gut microbiota 
by means of a fecal transplant (207, 208). Germ-free animals also 
display alterations in social behaviors (209, 210) and, insofar as it 
has been logistically possible to address in detail in this paradigm, 
aspects of cognitive function (211). Gut microbiota depletion us-
ing a cocktail of antibiotics from early adolescence in mice rep-
licates many of the behavioral characteristics of germ-free mice, 
including reduced anxiety-like behaviors and impaired cognitive 
performance (212). 
Other approaches have both largely supported and extended 
the behavioral picture painted by microbiota-deficient animals. 
For example, administration of a probiotic L. rhamnosus strain re-
duced anxiety and depression-related behaviors (213), while al-
ternative candidate probiotics, including a B. longum strain, ex-
erted a beneficial impact on cognitive processes (214). Prebiotics 
(e.g., fiber-rich foods that can influence the microbiome) can also 
exert anxiolytic effects (215), while bacterial infection with an en-
teric pathogen can impact both learning and memory (211) and 
modulate pain behaviors (216). 
Physiologically, germ-free animals also exhibit profound differ-
ences with conventionally colonized controls. These differences in-
clude a defective immune system and exaggerated corticosterone 
outputs to acute stressors (205, 217, 218). The microbiome is also 
required for the development of microglia, cells that defend the 
CNS. Microglia from germ-free mice had altered gene expression 
that influenced its development (219). 
An increased availability of tryptophan, the amino acid pre-
cursor to neuroactives such as serotonin and kynurenine pathway 
catabolites, as generated respectively by indoleamine 2, 3-dioxy-
genase (IDO1) or TPH, is one feature of the germ-free state (205, 
220, 221). Many aberrant physiologic features can be rescued if 
the animals are colonized with a normal microbiota, especially if 
this intervention takes place during specific time windows post-
weaning (205, 217). As is the case for behavior, other microbiota 
manipulations, such as rendering mice microbiota deficient or pro-
biotic ingestion by rodents, can also impact parameters such as 
corticosterone outputs or tryptophan availability (212, 213, 222). 
The reciprocal interaction between stress and the microbiome 
is a particularly interesting facet of this bidirectional relationship. 
As indicated above, the gut microbiota exert an influence on the 
hypothalamic–pituitary adrenal axis, the main host stress response 
system, and this can be captured by measuring cortisol in humans 
or corticosterone in rodents (223). There are now studies show-
ing that the opposite is also true and that a variety of stressful in-
sults that are linked to psychopathology in adulthood can alter the 
composition of the gut microbiome in animal models. This is re-
flected in studies that have examined early-life stress (224, 225), 
prenatal stress (226, 227), and psychosocial stress (228–230). In-
terestingly, the gut microbiota seems necessary for the expression 
of some of the pathologic behavioral features induced by mater-
nal separation (231), a well-validated early-life stress-based model 
of gut–brain axis dysfunction (232). In the clinical setting, mater-
nal prenatal stress is also associated with alterations in the infant 
gut microbiome (233). Another example of such feedback loop is 
stress-related microbiome–gut–brain axis dysfunction in irritable 
bowel syndrome (234). 
Growing up, germ-free influence biological function such as 
blood–brain barrier integrity (235), transcriptional regulation (203, 
236), neurogenesis (237) microglial function (238), and myelination 
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(239). Recently, it has been demonstrated that a germ-free mouse 
model of Alzheimer disease displayed a marked reduction of cere-
bral amyloid pathology and that colonization of these mice with 
the gut microbiota of their conventionally colonized counterparts 
reinstated the amyloid pathology (240). Although the behavioral 
implications of these altered amyloid phenotypes requires elab-
oration, this intriguing study does provide support for the hy-
pothesized role of the gut microbiota in neurodegenerative dis-
orders (241). 
The mechanisms underpinning influence of the gut microbiome 
on brain and behavior are under investigation. The gut microbiota 
is required for motor deficits, microglia activation, and α-synuclein 
pathology. Colonization of microbiota from Parkinson disease–
affected patients enhances physical impairments compared with 
microbiota transplants from healthy human donors. Thus, the gut 
bacteria are involved in movement disorders, and alterations in 
the human microbiome represent a risk factor for Parkinson dis-
ease (242). Recently, the role of the vagus nerve (the main neural 
communication highway between the gut and the brain) has at-
tracted much attention (243). It has been demonstrated, for ex-
ample, that the beneficial CNS impact of a probiotic was abolished 
in vagotomized mice (213), while the anxiety-like behaviors that 
emerge in a colitis model were absent in previously vagotomized 
mice (207). The vagus nerve is not the sole conduit linking the gut 
and the brain (244), and a variety of alternatives have been con-
sidered. These include microbial regulation of tryptophan metab-
olism (245), microbial metabolites, such as SCFAs (246) or indoles 
derived from tryptophan (247), neuropeptide production (248) as 
well as immunomodulation (249). The important role of the gut 
microbiota in maintaining intestinal barrier integrity also needs to 
be taken into account (250, 251). 
The landscape for manipulating the microbiome is broad and 
increasingly financed (252). Considerations are being given to 
priming interventions that promote assembly of the infant mi-
crobiome (65, 253, 254), sustain the gut microbiota in healthy 
aging (125, 126), more radical options such as fecal microbiota 
transplantation (255) as well as less controversial options such 
as psychobiotics (256), exercise (257, 258), and diet-based ma-
nipulations (259, 260). Indeed, a number of small studies using 
healthy volunteers have now demonstrated that ingestion of cer-
tain cocktails of probiotics, a fermented milk product with pro-
biotic or prebiotics, can impact on the CNS (261–264). Autism 
spectrum disorders are complex neurobiological disorders char-
acterized by impairment in social interaction and communication 
and restricted, repetitive, and stereotyped patterns of behavior, 
interests, and activities. Autistic children suffer from gastroin-
testinal disorders. Autistic children have less diverse microbial 
population in the gut and significantly lower abundances of the 
genera Prevotella, Coprococcus, and Veillonellaceae involved in 
carbohydrate metabolism (265). 
Future directions will likely see further elaboration of the role 
of the gut microbiome in sleep (266) and circadian rhythms (267–
269). Our awareness of the interface between natural and built 
environments, the gut microbiota, and human behavior is also 
growing (270–272). Of course, a key caveat is to what degree this 
promising but largely preclinical body of research will effectively 
impact the clinical setting. Moving from mouse to man, be it in the 
context of CNS-directed or gastrointestinal-focused research, is of 
course complicated for stress-related neuropsychiatric and other 
heterogeneous disorders associated with the gut microbiome (273, 
274). Of equal importance is the necessity to address the issue 
of whether the correlations that have been noted thus far be-
tween multiple disorders and the gut microbiota alterations are 
in fact causal relationships. Such obstacles are not insurmountable 
with due diligence and the necessary multidisciplinary expertise 
required to exploit the considerable opportunities presented by 
host–microbe interactions. 
Beneficial Microorganisms Restrict the 
Outgrowth of Pathogens in the Gut 
The human microbiota encompasses all the microorganisms 
that reside on the skin and in all other tissues and organs, includ-
ing the gastrointestinal tracts. Of these body sites, the gastrointes-
tinal tract is the most densely colonized organ. The microbiome in-
cludes bacteria, fungi, and archaea (275). There are approximately 
1,000 species of microbes colonizing the gut, with densities of 104 
to 105 bacteria per millimeter of digestive effluent in the proximal 
small intestine and 1011 bacteria per gram of luminal content in 
the colon (276). The physicochemical conditions in the gut influ-
ence the composition of the intestinal microbiota (277). The gas-
trointestinal tract harbors many distinct niches, each containing a 
different microbial ecosystem that varies according to the location 
within the gastrointestinal tract. The microbial density increases 
along the gastrointestinal tract with 101 to 104 microbial cells in the 
stomach and duodenum, 104 to 108 cells in the jejunum and ileum, 
to 1010 to 1012 cells per gram in the colon and feces (277–279). 
The majority of all microorganisms in the human digestive 
tract are bacteria and belong to two phyla, the Bacteroidetes and 
the Firmicutes (280). In addition, the other significant phyla occu-
pying the digestive tract include Proteobacteria, Actinobacteria, 
Fusobacteria, Spirochaetes, Verrucomicrobia, and Lentisphaerae 
(281, 282). The methanogens Methanobrevibacter and Metha-
nosphaera are the most dominant archaeal groups (7, 283). The 
two common fungal phyla in the gut include Ascomycota (which 
includes the genera Candida and Saccharomyces) and Basidio-
mycota (30, 284). 
Intestinal microbiota play a central role in the metabolic, nu-
tritional, physiologic, and immunological processes of the human 
body, processing indigestible dietary polysaccharides, including 
resistant starch and dietary fibers, thereby leading to the produc-
tion of important nutrients, such as SCFAs, vitamins (vitamin K, vi-
tamin B12, folic acid), and certain amino acids that humans are 
unable to synthesize themselves (279, 285, 286). The plant polysac-
charides in our diet are rich in xylan-, pectin-, and arabinose-con-
taining carbohydrate structures. The human genome lacks most 
of the enzymes required for degrading these glycans. Neverthe-
less, the distal gut microbiome provides us with this capacity to 
process these polysaccharides. The human gut microbiome is en-
riched for genes involved in glucose, galactose, fructose, arabi-
nose, mannose, and xylose, starch, and sucrose metabolism. Our 
microbiome also has significantly enriched metabolism of glycans, 
amino acids, and xenobiotics, methanogenesis, and 2-methyl-D-
erythritol 4-phosphate pathway–mediated biosynthesis of vitamins 
and isoprenoids (7). The intestinal microbiota also participates in 
the defense against pathogens by mechanisms such as coloniza-
tion resistance and production of antimicrobial compounds. Fur-
thermore, the intestinal microbiota is involved in the development, 
maturation, and maintenance of the gastrointestinal sensory and 
motoric functions, the intestinal barrier, and the mucosal immune 
The Host Microbiome Regulates  and Maintains  Human Health   11
system (279). The microbiota of the intestine is also involved in 
promoting bone formation as well as resorption, leading to skel-
etal growth. Microbiota induces the hormone insulin-like growth 
factor 1 (IGF-1), promoting bone growth and remodeling. When 
the microbiota ferment fiber, SCFAs are produced, leading to in-
duction of IGF-1 that promote bone growth (287). 
The very high microbial content of the large intestine poses 
a major challenge to the mucosal immune system, as it needs 
to tolerate commensal microbiota and dietary antigens while 
maintaining the ability to eliminate pathogens. Induction of co-
lonic Treg is crucial in fostering this immune homeostasis (288). 
CD4+CD25+FOXP3+ Tregs are of two types: thymus-derived Tregs 
(tTreg) and peripherally derived Tregs (pTreg). Although it is diffi-
cult to distinguish these types phenotypically, both are thought to 
have an essential role in immune regulation (288). Although tTregs 
develop in the thymus, the major site for pTreg development is the 
colon, resulting in a large population of regulatory cells that have 
a distinct T-cell receptor (TCR) repertoire and are critical for intes-
tinal homeostasis (152). Notably, the development of pTregs re-
quires microbiota to be present in the colon. Although the mech-
anism of induction of colonic pTregs is not understood, several 
microbial components have been found to enhance their expan-
sion and function, including SCFAs and polysaccharide A of Bac-
teroides fragilis (B. fragilis; ref. 288). Acetate, propionate, and bu-
tyrate are the three main SCFAs, and butyrate has been found to 
be the most potent inducer of colonic Tregs. 
The newborn infant is colonized at birth with microbes from the 
mother’s vaginal and fecal microbiota as well as with other envi-
ronmental microbes encountered in the first days of life (289). The 
mode of delivery influences the microbial composition in man. An 
article by Penders and colleagues (93) demonstrated that the im-
portant determinants of the gut microbiome composition in in-
fants were the mode of delivery, type of infant feeding, gestational 
age, infant hospitalization and antibiotic use in the infant. Term in-
fants born vaginally and exclusively breastfed had the most “ben-
eficial” gut microbiota (had the highest numbers of Bifidobacteria 
and lowest numbers of C. difficile and E. coli). In contrast, infants 
born through C-section had lower numbers of Bifidobacteria and 
Bacteroides, and they were more often colonized with C. difficile, 
as compared with vaginally born infants. Exclusively formula-fed 
infants were more often colonized with E. coli, C. difficile, Bacteroi-
des, and Lactobacilli, as compared with breastfed infants. Hospi-
talization and prematurity were associated with higher prevalence 
and counts of C. difficile. Administration of antibiotics to infants 
was associated with decreased numbers of Bifidobacteria and Bac-
teroides. Infants with older siblings had slightly higher numbers of 
Bifidobacteria, compared with infants without siblings (93, 290). 
C. difficile is an opportunistic, anaerobic Gram-positive, spore-
forming, toxin-producing bacillus that is transmitted among hu-
mans through the fecal–oral route. Notably, the pathogen is gen-
erally present in the human gut, but it does not cause any disease 
under normal conditions. Abuse/misuse of antibiotics destroys 
beneficial microbiota that enables the proliferation of C. difficile, 
leading to pathogenic conditions. Ampicillin, amoxicillin, cepha-
losporins, clindamycin, and fluoroquinolones are the antibiotics 
most frequently associated with disease, but almost all antibiot-
ics have been associated with increased rates of opportunistic in-
fection. C. difficile colonizes the large intestine and releases the 
exotoxins TcdA and TcdB that cause colitis in susceptible persons 
(291, 292). C. difficile has emerged as a major enteric pathogen 
with worldwide distribution. In the United States, C. difficile is 
the most frequently reported nosocomial (i.e., hospital-acquired) 
pathogen. A recent surveillance study identified 453,000 cases of 
C. difficile infection and 29,000 deaths associated with C. difficile 
infection; approximately, a quarter of those infections were com-
munity acquired (293). The antibiotics prescribed to control C. 
difficile include metronidazole, vancomycin, fidaxomicin, or sur-
gery in extreme cases of infection (294). Fecal transplant is emerg-
ing as an alternative strategy for treating recurrent C. difficile in-
fections (295). Use of probiotics (such as beneficial bacteria and 
yeast), which help restore a healthy balance to the intestinal tract, 
is safe and effective for preventing C. difficile–associated diarrhea 
(296). Thus, beneficial microorganisms are essential to maintain 
the human gut immune homeostasis, thereby preventing patho-
genic infections. Further contributing to such defenses, benefi-
cial microorganisms also modulate epithelial cell proliferation, vil-
lus architecture, and angiogenesis within the intestine, along with 
xenobiotic metabolism, bone mineral density, behavior, and key 
metabolic functions (297, 298). Tipping the balance favoring the 
expansion of enterobacteria is one of the causes of several inflam-
matory bowel diseases. However, it is not known how the favorable 
bacteria prevent dysbiosis. A recent study demonstrated that mi-
crocins, the small proteins secreted by several favorable bacteria 
could limit the expansion of competing Enterobacteriaceae (299). 
Microbiome Effects on Intestinal Barrier 
Function and Inflammatory Bowel Disease 
Mammals, including humans, support one of the most complex 
microbial ecosystems. Although the immune system is classically 
thought to have evolved to provide protection from infection by 
microbial pathogens, animals peacefully coexist with a vast and 
complex microbiota, which extensively interacts with the immune 
system. It has recently been proposed that the total information 
encoded by the mammalian genome is not sufficient to carry out 
all functions that are required to maintain health and that products 
of our microbiome are crucial for protection from various diseases 
(300). It is possible that alterations in the development or com-
position of the microbiota (dysbiosis) disturb the partnership be-
tween the microbiota and the human immune system, ultimately 
leading to altered immune responses that may underlie various 
human inflammatory disorders (146). 
In inflammatory bowel disease (IBD), the role and interplay of 
the microbiome (301–303) with a gastrointestinal barrier compro-
mise (304–306) has been the subject of extensive review (307–
311). Gastrointestinal barrier function is not governed solely by 
the tight junctional complex, although this focus has certainly 
attracted the greatest basic research interest. Tight junctions 
form the continuous intercellular barrier around epithelial cells, 
which are required to separate tissue spaces and regulate selec-
tive movement of solutes across the epithelium (312). From a 
wider perspective, gastrointestinal barrier function also may be 
compromised by an impaired mucus layer over the epithelium 
[a topic reviewed nicely by others recently (Chen and colleagues; 
ref. 313)], as well as by cell death in the epithelium or an epithe-
lial–mesenchymal transition leading to impaired cell adhesion/ 
attachment (to other cells and substratum). Leak at the sites of 
compromised tight junctions may be quite distinct in nature from 
the leak at the sites of cell death (314). Likewise, the remediation 
of leak is very different in these cases; repair of leak from im-
paired tight junctions may be a purely transcription/ translation/
phosphorylation–based process, whereas remediation of leak due 
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to cell death/dedifferentiation/detachment could also require a 
careful orchestration of cell motility and cell replication. In these 
different cases, the microbiome may exert control over very dif-
ferent processes. It is worth considering that any given specific 
case of IBD likely involves gastrointestinal leak from all of these 
causes, and therefore alleviation of such leak, and the inflam-
matory cascades it gives rise to, is a quite complex task. Further 
research is required to determine whether microbiome may be 
better at repair of one type of leak than the other. 
There is no doubt that IBD is in part driven by a breakdown or 
compromise of the gastrointestinal epithelial barrier, and many 
reviews on IBD have dealt with this feature as mentioned above. 
There is some controversy concerning whether a compromise of 
barrier function is the initial causation of the disease. The find-
ings that asymptomatic, first-degree relatives of IBD patients in 
fact harbor molecular-level leak in their gastrointestinal tract mu-
cosa have traditionally been powerful evidence tilting the argu-
ment toward causality (315, 316). The question of course that 
leaps to the fore then is what induces the leak in the first place? 
The very fact that a genetic element exists in IBD (e.g., in first-
degree relatives) indicates a role for genetics in the disease, but 
equally obvious is that genetics is probably a necessary but in-
sufficient condition. 
Studies focusing on this involvement of gastrointestinal micro-
biome in IBD take two forms: (i) whether the microbiome is abnor-
mal in IBD and possibly playing a role in etiology; (ii) whether a 
microbiome modification can be designed as a therapeutic option 
in the disease. The second possibility appears achievable: Some 
of the best clinical evidence, on the basis of its very applicability, 
is the success of “fecal transplant” procedures in achieving thera-
peutic efficacy in IBD (317, 318). Prior to the recent advent of these 
protocols, there was the use of butyrate enemas to achieve ther-
apeutic relief (286, 319, 320). The therapeutic efficacy of luminal 
administration of butyrate is cogent testimony to the positive role 
played by the normal microbiome in maintaining a functional ep-
ithelial barrier in the gastrointestinal tract, as well as to the utility 
of targeting the microbiome as a viable clinical approach to IBD. 
Butyrate is a significant metabolite of dietary fiber by the normal 
gastrointestinal microbiota (321), with butyrate levels in the gas-
trointestinal lumen being the highest in the body. Butyrate has 
been found in many recent in vitro studies to be highly effective 
in inducing structural changes to the epithelial tight junction com-
plex, resulting in improved epithelial barrier function (322, 323). 
A similar literature also exists for the gastrointestinal microbiota 
metabolite, indole, a product of tryptophan metabolism by com-
mensal bacteria (324, 325). In combination, the fecal transplant 
and butyrate enema clinical studies, along with the in vitro stud-
ies of tight junction modification and enhancement by butyrate 
and indole, provide a very powerful argument of not only mainte-
nance and modification of the gastrointestinal barrier by the mi-
crobiota, but also for targeting the microbiota as a viable, effec-
tive therapeutic strategy. 
Better delineated proof of the ability of the microbiota to both 
positively and negatively affect the gastrointestinal barrier comes 
out of animal model and epithelial cell culture studies. For ex-
ample, the probiotic bacterium, L. casei, both strengthened bar-
rier function and decreased proinflammatory cytokine content in 
BALB/c mice (326). In addition, such treatment also modified the 
gastrointestinal microbiota overall. The probiotic and commen-
sal bacteria L. rhamnosus and F. prausnitzii have also improved 
barrier function, as demonstrated in studies with CACO-2 cell cul-
ture models and experimentally induced colitis in C57BL/6 mice 
(327, 328). The microbiome is also known to be involved in the 
wound healing of the mucosa of the gut (329). In mice, it has 
been demonstrated that mucosal injury leads to increase in the 
expression of formyl peptide receptor 1 (FPR1) and neutrophilic 
NADPH oxidase (NOX2) that causes depletion of oxygen resulting 
in the enrichment of anaerobic bacteria. The anaerobic, mucino-
philic gut symbiont, A. muciniphila, stimulated proliferation and 
migration of enterocytes adjacent to the colonic wounds medi-
ated through FPR1 and intestinal epithelial cell–specific, NOX1-
dependent redox signaling, thereby leading to wound healing 
of the mucosa. These findings highlight a very important con-
sideration in studies of the microbiota, barrier function, and IBD, 
namely that not only can microbiota affect barrier function, but 
modification of barrier function (good and bad) may well affect 
microbiota composition, a “research road less traveled.” This less 
investigated area is well illustrated by the finding that anti-TNF 
immunologic medications, which reduce proinflammatory cyto-
kines and allow for barrier repair, also result in changes in micro-
biota composition (330). 
It is worth noting too that a factor as omnipresent as diet can 
affect both barrier function and microbiota while also simulta-
neously affecting cytokine production. Administering a high-fat 
“Western” diet to CEABAC10 mice induced deleterious changes 
in gastrointestinal microbiota (e.g., increased content of adher-
ent-invasive E. coli), decreased mucus layer protection, and led to 
gastrointestinal barrier compromise (331). Pathogenic E. coli have 
been implicated in Crohn disease, in part due to an ability to not 
produce cell death while inducing synthesis of copious amounts 
of TNF (332). The dietary connection to an altered microbiota in 
terms of pathogenic bacteria is also apparent in the finding that vi-
tamin D deficiency enables the barrier-disruptive effects of patho-
genic E. coli to be manifested (333). Even more fascinating and less 
intuitive is an effect of the environment at large on barrier func-
tion, microbiota, and inflammatory status, as Kish and colleagues 
(334) show for particulate air pollutants. It will be instructive to dis-
cover in future research whether the principal actions of diet/nu-
trition/ environment are on microbiota directly and barrier func-
tion indirectly, or vice versa. 
As more and more studies reveal the intricate interplay be-
tween gastrointestinal barrier function, gastrointestinal microbi-
ota, and degree of inflammation, it is worth considering that the 
effects of microbiota on barrier function, and barrier function on 
microbiota, will in large degree derive from actions of protein ki-
nases in signaling pathway transduction systems. This has been re-
cently very well reviewed by Yang and Yan (335). One would cau-
tion however against taking an aggressively reductionist approach 
in dealing with the interplay of microbiota, barrier function, and 
inflammation: The complexity of the gut microbiome in the gas-
trointestinal tract, the complexity of the signaling pathways known 
to regulate barrier function, and the complexity of cytokine inter-
actions all suggest strongly that one needs to tread carefully in 
what may well be overly ambitious undertakings to find and uti-
lize specific molecular mechanisms involved in this intricate rela-
tionship. A properly functioning gastrointestinal mucosa is in es-
sence a symphony scored by microbiota “strings,” barrier function 
“woodwinds,” and immune regulatory “brass.” To search for an all-
pivotal kinase or phosphatase responsible for gastrointestinal mu-
cosal homeostasis may be analogous to trying to claim a single 
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flute or viola as the fulcrum of Beethoven’s Ninth, a fool’s errand 
that ignores the extreme complexity and subtlety of the gastro-
intestinal environment. 
Because of the still singular importance of the studies showing 
epithelial barrier compromise in asymptomatic first-degree rela-
tives of IBD patients to the field of IBD research, it will be very in-
teresting to observe the outcome of studies yet to be performed 
on the microbiome of first-degree relatives of IBD patients. It is 
likely that those results could be just as pivotal to the future un-
derstanding of IBD as were the now-long-ago studies of May and 
Hollander on barrier function and IBD (315, 316). 
Increased risk of developing IBD may be due to improved hy-
giene practices. Ramanan and colleagues (336) showed that in-
testinal helminth infection, caused by parasitic worms, protects 
IBD-susceptible mice from developing the disease. The infection 
of parasitic worms increased specific protective species and lim-
ited other inflammatory members of the microbiota. People from 
helminth-endemic regions harbored a similar protective microbi-
ota, and their deworming led to an increase in inflammatory Bac-
teroidales, as observed in the mice. Thus, a changing microbial 
environment may shape susceptibility to inflammatory disease. 
Although we currently know at least a partial membership of 
the human microbiome, we are yet to fully understand how these 
microorganisms are contained in the intestine. Anatomy of the 
colon by light microscope reveals a mucus layer, mucosa, submu-
cosa, gut-associated lymphoid follicle, and muscularis. The intes-
tinal/colonic mucus is an efficient system for protecting the epi-
thelium from bacteria by promoting their clearance and separating 
them from the epithelial cells, thereby inhibiting inflammation and 
infection (337). Colonic mucus is produced by the goblet cell. The 
main mucus component in the intestine is MUC2 mucin, a large 
and heavily O-glycosylated gel-forming mucin that forms enor-
mous polymeric nets by C-terminal dimerization and N-terminal 
trimerization. Upon secretion from the goblet cells, the mucus ex-
pands rapidly and builds a stratified dense layer that is attached to 
the epithelium. Normal human sigmoid colon has an inner mucus 
layer that is impenetrable to bacteria. At a distance far from the 
epithelial surface, the inner mucus is transformed into a soluble 
and less organized outer mucus layer that by proteolytic expansion 
generates the preferred habitat for the commensal microbes (338). 
IBDs are characterized by aberrant innate and adaptive immune 
responses to commensal luminal bacteria (339). Ulcerative colitis 
is thought to be caused by some strains of E. coli (340). In cell cul-
ture models, it has been shown that ulcerative colitis-associated 
E. coli producing α-hemolysin can cause rapid loss of tight junc-
tion integrity (341). The human intestinal epithelium is formed by 
a single layer of epithelial cells that separates the intestinal lumen 
from the underlying lamina propria and the space between these 
cells is sealed by the tight junction, which regulates the permea-
bility of the intestinal barrier (342). Tight junction complexes al-
low passive absorption of small hydrophilic molecules (nutrients 
and ions), but they restrict passage of large molecules and infec-
tious microbes. Ulcerative colitis is characterized by a leaky in-
testinal barrier due in part to defective tight junction. Our group 
had reported that attenuation of the Bin1 gene in a mouse model 
would protect against experimental colitis (343). On the basis of 
the study, we recently demonstrated that treatment of experimen-
tal colitis with Bin1 mAb would support mucosal barrier function 
by inducing the expression of tight junction proteins, thereby pro-
tecting the integrity of the lymphoid follicle. The therapy may be a 
novel strategy to treat ulcerative colitis and possibly limit risks of 
colorectal cancer (344). Thus, lowering Bin1 levels may be a strat-
egy that would lead to enhanced tight junction proteins that, in 
turn, protects against pathogenic microorganisms crossing the 
epithelial cells. 
Other strategies may be used by the epithelial cells to protect 
against pathogenic microbes from entering the tissues. Recently, 
while working on subconfluent CACO-2 cells (derived from the 
intestine), we observed that EEA1 endosomes (early endosome 
marker) were confined more toward the periphery of CACO-2 cell 
monolayers. To confirm whether these endosomes are present 
in the colon tissues, we stained for EEA1 in mouse colonic tis-
sues. We observed EEA1 endosomes in the peripheral mucosa 
as well as in the muscularis. Insofar, as endosomes are tradition-
ally thought to protect against foreign bodies, including microor-
ganisms, one might speculate that early endosomes help protect 
against bacteria crossing the mucus. Microbes that overcome this 
barrier to cross the mucus layer might be destroyed within endo-
somes, with further protection afforded by the endosomes lining 
the muscularis (Fig. 1).  
Additional endosomal strategies may be used to protect co-
lonic tissues against the entry of pathogenic microbes. Endosomes 
are traditionally thought to protect colonic epithelial cell layers 
against microorganisms, possibly helping eliminate bacteria that 
Figure 1. Early endosomes localize mainly to the periphery of colon mucosa and muscularis. A, Peripheral localization of EEA1 in a colony of human 
colonic Caco-2 cells. Cells were stained with the early endosomal marker EEA1 (green) and DAPI to visualize cell nuclei (blue) and processed for im-
munofluorescence microscopy. B, Peripheral localization of EEA1 in murine colon mucosa processed as above. C, Peripheral localization of EEA1 in 
murine colon muscularis processed as above.  
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cross the mucus layer, a strategy that also may be extended into 
the subordinate muscularis layer (Fig. 1). In subconfluent human 
colonic cells, which form island-like colonies in monolayer culture, 
the early endosome marker EEA1 can be seen to preferentially lo-
calize to the colony periphery. Similarly, in colon tissues, early en-
dosomes display the same localization with EEA1 staining in the 
periphery of the mucosa and muscularis. Beclin1-dependent au-
tophagy associated with the endosome pathway also has been 
implicated in the bacterial and viral pathogen elimination (345), 
which downregulates Beclin1 to promote virulence and infection. 
Beclin1 associates with endosomes and regulates EEA1/early en-
dosome localization and late endosome formation (346). Upon 
TLR signaling, Beclin1 rapidly translocates to the phagosome and 
mediates efficient phagosome–lysosome fusion to ensure rapid 
acidification and efficient destruction of the pathogen (345). In 
human colonic cells, Beclin1 staining occurs throughout the colon 
tissue at endosomes (Fig. 2), possibly helping direct pathogenic 
cargo to lysosomes and thereby restricting microbiome ecology 
to the gut lumen. 
IDO1 and the Microbiome–Host Interaction 
As noted above, establishing and maintaining the symbiotic 
mutualism that exists between the microbiome and its mamma-
lian host necessitates the engagement of mechanisms of acquired 
immune tolerance, as these microorganisms represent the epit-
ome of non-self. IDO1 is a metabolic enzyme that has gained rec-
ognition as an important mediator of acquired immune tolerance. 
IDO1 catalyzes the rate-limiting first step in the degradation of the 
essential amino acid tryptophan, but is not involved in maintain-
ing tryptophan homeostasis, which instead is the role of the dis-
tinct liver enzyme TDO2 (tryptophan dioxygenase; ref. 347). The 
concept of IDO1 as an immune regulator emerged from findings 
that tryptophan catabolism could suppress cytotoxic T-cell acti-
vation (348, 349). The demonstration that the IDO pathway inhib-
itor 1-methyl-tryptophan (1MT) could elicit T-cell– dependent re-
jection of allogeneic mouse concepti (350, 351) established the 
physiologic relevance of tryptophan catabolism as a mediator of 
acquired immune tolerance. Subsequent findings linking attenu-
ation of the tumor suppressor gene Bin1 to IDO1 dysregulation 
and tumoral immune escape (352) provided experimental sub-
stantiation for the corollary proposition that tumor cells might, by 
inducing IDO1, appropriate this mechanism of protection for the 
“foreign” fetus to overcome immunosurveillance. Within the com-
plex inflammatory milieu of the tumor microenvironment, IDO1 
induction is not necessarily restricted to tumor cells, and nonma-
lignant stromal cells expressing IDO1 can promote tumoral im-
mune escape as well (353). In particular, IDO1 induction in anti-
gen-presenting cells (APC), such as DCs and macrophages, has 
been implicated in promoting immune tolerance by suppressing 
effector cytotoxic T lymphocytes, converting naïve T lymphocytes 
to FoxP3+ Treg cells and elevating the suppressive activity of “nat-
ural” Tregs (354). 
A great deal of attention is now focused on the therapeutic po-
tential of small-molecule inhibitors of IDO1 for treating cancer pa-
tients (355), particularly in combination with cancer chemotherapy 
or “immune checkpoint” antibodies (352, 356). It is not yet clear 
how IDO1 may influence host interactions with the microbiome, 
but there has been much attention to the related topic of its role 
in the host response to infection by various pathogens, which has 
been a topic of interest for a number of years. Indeed, well prior 
to findings of its involvement in immune modulation, it was noted 
that intraperitoneal administration of bacterial LPS could induce 
IDO1 activity in the lungs of mice by 30- to 50-fold (357). This ini-
tial indication that IDO1 induction might be associated with the 
inflammatory response to microbial infection was followed by re-
ports of pulmonary IDO1 induction in response to virus infection 
(358) and IFNγ (359). 
As IFNγ plays a major role in controlling a variety of infections, 
the finding that IDO1 is highly responsive to IFNγ spurred in-
vestigations addressing whether IDO1 might have a downstream 
antimicrobial effector role. In 1984, Pfefferkorn and colleagues 
reported that tryptophan degradation was responsible for the 
IFNγ-mediated restriction of the growth of the obligate intracel-
lular protozoan Toxoplasma gondii (T. gondii) in human fibroblasts 
(359). IFNγ-mediated restriction of the growth of the obligate, in-
tracellular, Gram-negative bacterium Chlamydophila psittaci was 
likewise linked to tryptophan deprivation (360). These studies fo-
cused attention on IFNγ-elicited tryptophan deprivation result-
ing from the induction of IDO1 as mediating the antiprolifera-
tive effect on these intracellular pathogens. This assessment, that 
IDO1 provides a beneficial effect in combating infections, was 
complicated by additional studies demonstrating the activation 
of genes for Chlamydia persistence triggered by IDO1-mediated 
Figure 2. Late endosomes locate throughout colon mucosa and muscularis. A, Punctate cytosolic localization in a colony of human colonic Caco-2 
cells. Cells were stained with Beclin1, an autophagic regulator associated with late endosomes (green), and DAPI to visualize cell nuclei (blue) and 
processed for immunofluorescence microscopy. B, Cytosolic localization of Beclin1 in murine colon mucosa processed as above. C, Cytosolic local-
ization of Beclin1 in murine colon muscularis processed as above.  
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tryptophan depletion. Because the bacterium is sensitive to the 
antibiotic treatment only when it is metabolically active, IDO1 ac-
tivity in this context was detrimental to clearing infections, lead-
ing to the suggestion that tryptophan supplementation might help 
overcome antibiotic resistance (361). Furthermore, although the 
effects of IDO1 on microorganisms were initially attributed to de-
pletion of tryptophan, evidence of microbial effects produced by 
downstream tryptophan metabolites, from what is collectively re-
ferred to as the kynurenine pathway, were also reported (362, 363). 
In particular, 3-hydroxykynurenine was shown to suppress the pro-
liferation of S. aureus in vascular allografts (364), and both 3-hy-
droxykynurenine and 3-hydroxyanthranilic acid were found to con-
tribute to controlling the replication of Trypanosoma cruzi in mice 
(365). In a single report, treatment with 1MT produced three dif-
ferent outcomes depending on the nature of the infection, exac-
erbating T. gondii toxoplasmosis, restraining L. major leishmania-
sis, and having no apparent effect on HSV-1 replication or latency 
(366). In aggregate, the implication from these studies of infec-
tious pathogens is that the overall impact of IDO1 activity, both in 
terms of tryptophan depletion and the production of various me-
tabolites, on the diverse ecology of the commensal microbiome 
is likely to be complex and contextual. 
Perhaps even more consequential than the direct effects of 
IDO1 activity on particular microbes are the effects that IDO1 can 
exert on the overall inflammatory environment. In accord with its 
ability to elicit T-cell suppression, the general assumption has been 
that IDO1 should act in an immunosuppressive manner to limit the 
severity of inflammation. Data supporting this interpretation have 
been reported in a mouse model of chronic granulomatous dis-
ease in which defective IDO1 function in mice lacking an essential 
component of NADPH oxidase, p47phox, was implicated in the ex-
aggerated inflammatory response to infection with Aspergillus fu-
migatus (367). The more severe illness was associated with higher 
numbers of IL17-producing γδT cells and fewer IL10-producing 
αβTregs, which could be reversed by the provision of exogenous 
kynurenine. However, as with the effects of tryptophan catabo-
lism on microorganisms, the categorization of IDO1 as strictly im-
munosuppressive may be an oversimplification (368). In a mouse 
model of chemical carcinogenesis, genetic loss of IDO1 did not ex-
acerbate inflammation in response to phorbol ester–elicited tumor 
promotion, as would be expected if it were broadly immunosup-
pressive, but did result in a dramatically reduced incidence of pre-
malignant lesions (369). Perhaps even more strikingly, in a mouse 
model of rheumatoid arthritis, 1MT treatment suppressed rather 
than exacerbated joint inflammation (370), whereas in a contact 
hypersensitivity model, genetic loss of IDO1 resulted in diminished 
ear swelling (371). Why IDO1 has such varied effects on the in-
flammatory response remains to be fully elucidated, but suggests 
that the outcome of the interactions with the complex microbi-
ome may be contextual and difficult to predict. 
The study in the rheumatoid arthritis model noted above also 
highlights a particular complication with interpreting results of the 
many studies that have relied on the use of the compound 1MT to 
inhibit IDO1 activity. Biochemical and pharmacologic evaluation 
of this compound clearly indicates that it is not directly inhibiting 
the enzyme at the dose ranges administered in vivo, and it is able 
to signal as a mimetic for tryptophan sufficiency and thereby in-
terfere with activation of downstream response pathways (372). 
However, a tryptophan deficiency signal can be provided by any 
of the enzymes that catalyze tryptophan degradation (IDO1, IDO2, 
TDO2, as well as TPH, the latter of which initiates an alternate path-
way of tryptophan catabolism to serotonin). Therefore, 1MT is not 
a valid tool to discriminate which of these particular enzymes is in-
volved. Indeed, in the rheumatoid arthritis model, genetic analysis 
revealed that the recently identified paralog IDO2, and not IDO1, 
is likely to be responsible for the effect of 1MT on joint inflamma-
tion, as the effect of 1MT administration was phenocopied in mice 
lacking IDO2 but not IDO1 (370, 373). Studies using later gener-
ation, direct enzyme inhibitors (355), coupled with studies in ge-
netically modified animals (371, 374, 375) can overcome ambigu-
ities in data interpretation associated with 1MT treatment. Indeed, 
a recent study of LPS responses utilizing the IDO1, IDO2, and Tdo2 
gene deletion mouse strains provides confirmatory evidence that 
these three genes have distinct, nonoverlapping roles in the host 
immune response to this microbial signal (376). 
Although the regional microbiome present at all barrier sur-
faces is likely to influence immunity locally, the microbiome of 
the gastrointestinal tract is of particular interest because of the 
broader role it has been found to play in shaping systemic im-
mune homeostasis (377). Correspondingly, current microbiome 
research is largely focused on the gastrointestinal tract, where 
commensal microorganisms have been found to contribute to 
host defense by limiting the growth of enteric pathogens and 
producing symbiosis factors that control intestinal inflamma-
tion and pathology (377). Evidence implicating IDO1 in this pro-
cess has come from a study of the protective capacity of L. sal-
ivarius, which is abolished in mice lacking the gene encoding 
NOD2, an intracellular pattern recognition molecule that regu-
lates inflammatory pathways in response to detection of bacte-
rial peptidoglycans. In this model, IDO1 upregulation was found 
to correlate with NOD2-dependent protection (378). The in-
creased regulatory complexity imposed by the gut microbiome 
may help also explain counterintuitive findings associated with 
IDO1 in this tissue. In a dextran sodium sulfate/1,2-dimethylhy-
drazine–elicited model of colon carcinogenesis, genetic loss of 
IDO1 resulted in increased tumor frequency (379), unlike other 
organ systems in which IDO1 loss has been associated with re-
sistance to carcinoma development (380, 381). This outcome is 
similar to the atypical impact on tumor formation ascribed to 
Tregs in the gut, where their presence appears to be protec-
tive against carcinogenesis (382), despite evidence that Tregs are 
generally associated in other organs with tumor promotion. It 
has been proposed that the effect of immunosuppressive mech-
anisms on inflammatory pathology of the gut may be quite dif-
ferent depending on whether there is any initial involvement of 
tissue damage, as the resulting microbial translocation produces 
a severe tumor-promoting inflammation (383). Under these cir-
cumstances, dampening the inflammatory response via immu-
nosuppressive mechanisms may provide a more consequential 
benefit that overshadows any detrimental role in promoting im-
mune escape. This interpretation is consistent with the findings 
of two otherwise apparently contradictory studies in colitis mod-
els, where IDO1 blockade resulted in augmented colitis induced 
by trinitrobenzene sulfonic acid (384), but diminished colitis in-
duced by Citrobacter rodentium (385). 
In conjunction with the complex immunoregulatory effects 
attributed to IDO1 activity in the gut, tryptophan metabolites 
produced by the microbiota affect mucosal reactivity. When 
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switching from sugar to tryptophan as an energy source, the 
highly adaptive Lactobacilli in the gut expand and produce an 
aryl hydrocarbon receptor (AhR) ligand, indole-3-aldehyde, that 
contributes to AhR-dependent IL22 transcription. The result-
ing IL22- dependent mucosal response promotes the survival of 
mixed microbial communities, while providing colonization re-
sistance to the fungus Candida albicans and mucosal protection 
from inflammation. This example of coevolutionary commensal-
ism through the microbiota–AhR axis represents yet another way 
in which tryptophan catabolism appears to be involved in fine 
tuning host mucosal reactivity (386). As further investigations 
into the physiologic and pathophysiologic interactions between 
IDO1, the commensal microbiome and host immunity are con-
ducted, the indications from these early studies are that IDO1 is 
likely to play an integral but contextual role at the interface be-
tween homeostasis and dysbiosis. 
Microbiome and Cancer 
The interplay between microbes, cancer, and the immune sys-
tem is in no manner fully defined. However, accumulating evidence 
argues provocatively that microbes exert a variety of functions on 
host oncogenesis, tumor progression, and response to immuno-
therapy. Thus, selectively manipulating the gut microbiome is a 
critical parameter to consider in the ongoing battle against es-
tablished cancers. 
The metabolic potential of the gut microbiota is now regarded 
as vital to the process of malignant transformation. Disruption of 
the intimate relationship between the host and intestinal bacte-
ria, known as dysbiosis, can affect oncogenesis, tumor progres-
sion, and response to cancer therapy. Dysbiosis can occur for sev-
eral reasons: (i) direct occupancy of unwanted, foreign microbes 
(as discussed above) that outcompete friendly gut flora; (ii) a re-
sponse to immunosenescence with aging; and (iii) direct environ-
mental insults such as antibiotics and smoking (387). In the set-
ting of chronic autoimmune processes, such as Crohn’s disease 
and ulcerative colitis, the integrity of gut epithelial, myeloid, and 
lymphoid components is disrupted (Fig. 3). These chronic insults 
ultimately increase host’s risk for neoplastic transformation (388). 
Indeed, several factors that favor carcinogenesis similarly recapit-
ulate dysbiosis. 
One well-studied model of the dysbiosis/cancer connection is 
that of repeated intra-abdominal infections, the use of antibiot-
ics, or both leading to an increased incidence of colorectal cancer 
(389). In several preclinical studies, interventions that abrogate or 
directly alter gut microbiome composition increase the incidence 
and progression of colorectal carcinoma in both genetic and car-
cinogen-induced models of tumorigenesis (390–392). Moreover, 
several byproducts of the gut microbiota directly target intestinal 
epithelial cells and either facilitate oncogenesis (as reported for 
hydrogen sulfide and the B. fragilis toxin) or suppress tumorigen-
esis (in the case of SCFAs; ref. 393). Intestinal microbes have been 
characterized to participate in more than just colorectal carcino-
genesis. Experimental models of gut flora also elucidate the de-
velopment of other extraintestinal cancers, such as hepatocellular 
carcinoma (394, 395), presumably through systemically dissemi-
nated metabolic networks. Helicobacter pylori (H. pylori) is a Gram-
negative bacterial pathogen that selectively colonizes the gastric 
epithelium. It is postulated that half of the world’s population is 
infected with H. pylori, although colonization of the pathogenic 
bacteria does not cause any symptoms in a majority of the pop-
ulation. Nevertheless, long-term carriage of H. pylori significantly 
increases the risk of developing diseases. Among infected indi-
viduals, approximately 10% develop peptic ulcer disease, 1% to 
3% develop gastric adenocarcinoma, and <0.1% develop mucosa-
associated lymphoid tissue (MALT) lymphoma. However, at initial 
stages, gastric MALT lymphoma can be cured completely by the 
eradication of H. pylori with antibiotics (396). 
Apart from antibiotics, probiotics may also inhibit tumorigene-
sis and cancer progression. Konishi and colleagues (397) reported 
that the culture supernatant of L. casei has tumor-suppressive ef-
fect on colon cancer cells. The authors reported that ferrichrome 
produced by L. casei is the molecule that provides tumor protec-
tion and is exerted via the JNK signaling pathway. 
The etiology of breast cancer is still not understood, although 
it is believed the disease is due to a combination of both ge-
netic and environmental factors. It is posited that environmen-
tal factors influence breast cancer, as there is an increased inci-
dence of breast cancer among migrants and their descendants 
after they move from a region of low breast cancer risk to a re-
gion of high risk. Bacterial communities within the host could be 
one such environmental factor that may influence breast can-
cer development. Different bacterial profiles in breast tissue ex-
ist between healthy women and those with breast cancer. Breast 
cancer patients had higher levels of Bacillus, Enterobacteriaceae, 
and Staphylococcus. E.coli and Staphylococcus epidermidis iso-
lated from breast cancer patients induced DNA double-stranded 
breaks in HeLa cells. There was also a decrease in some lactic 
acid bacteria, known for their beneficial health effects, includ-
ing anticarcinogenic properties (398). It has been demonstrated 
that women who drink fermented milk products have a reduced 
risk of breast cancer development (399). Oral administration of 
Lactobacillus species has been shown to be protective in animal 
models of breast cancer (400). 
Case studies back to the 1700s have recounted the develop-
ment of bacterial infections in cancer patients that led to remis-
sions of their malignant disease. One of the pioneers in this field, 
the U.S. surgeon William B. Coley, engaged in a lifelong study of 
this phenomenon after the loss of his very first patient in the late 
1800s to a rapidly invasive sarcoma (401). Searching the literature 
available, Coley discovered records of another sarcoma patient 
with relentless sarcomatous recurrences following surgical resec-
tion and an ultimate wound infection (erysipelas) with Strepto-
coccus pyogenes (S. pyogenes) and high fever. To his surprise, after 
each attack of fever, the ulcer improved, the sarcoma shrank, and 
the lesion ultimately regressed completely. Coley suspected that 
in some manner, the infection had induced tumor regression and 
began a series of trials to “cure” his cancer patients with patho-
gen inoculation. He infected his next 10 patients, but observed 
intrinsic variability in efficacy using this method (402). Because of 
this unpredictability, he elected to create a formulation containing 
two killed bacteria: S. pyogenes and Serratia marcescens. Under the 
form of an inactivated vaccine, he could simulate an infection (in-
flammation, chills, fever) without the actual risks of a life-threat-
ening disease. This vaccine became known as ``Coley toxins.’’ The 
relative success with Coley’s vaccine was by no means limited to 
sarcomas. For decades, this vaccine form had been used by other 
contemporaries for carcinomas, lymphomas, melanomas, and my-
elomas (403, 404). 
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However, with the advent of radiotherapy and chemotherapy, 
and the empowerment of the FDA in 1964 that restricted clinical 
use of “Coley toxins,” the use of microbial toxins in oncology fell 
out of use. There were, however, rare instances in which this line 
of thinking endured and eventually received FDA approval. Per-
haps the most prominent example is the use of Bacillus Calmette–
Guerin (BCG) for the treatment for superficial bladder cancer (405). 
BCG is currently the only conventional bacterial vaccine in use 
for direct tumor killing. Unlike Coley toxins, BCG is not adminis-
tered with the ultimate goal of induced fever. But similar to Col-
ey’s methods, the vaccine is applied directly to the tumor site with 
repeated courses following initial resection to prevent recurrence 
(406). After intravesicular administration of this vaccine, a wide 
range of cytokines become detectable in the urine, including IL1, 
IL2, IL6, IL8, IL10, IL12, IL18, IFNγ, IFNγ-inducible protein-10, mac-
rophage colony-stimulating factor, and TNFα (407–409). This in-
flammatory host response illustrates the point that individual im-
munomodulating cytokines are partial components of a much 
more complex immunologic response to infection, and corre-
spondingly, tumor regression. Some insights were gleaned from 
Coley toxins and other historical reports on live or attenuated 
bacterial inoculations. One was that a local inoculation produces 
only a local response. Thus, BCG use is limited to superficial blad-
der cancer. The heat and immune activation associated with local 
Figure 3. Dysbiosis: an immunocompromised state characterized by pathobiont colonization that leads to hyperinflammation, dysplasia, and tumor-
igenesis. Symbiosis (left): a symbiotic gut microbiota operates under a functional intestinal epithelial cell barrier, with steady-state proportions of 
mucus, pattern recognition receptors, antimicrobial peptides, and secretory IgA, which in turn contain the microbiota in the intestinal lumen. Under 
tight control by intestinal epithelial cells, the intestinal immune system within the gut lamina propria becomes largely tolerant to the resident com-
mensals. Signaling cascades that occur downstream of TLRs are used by intestinal epithelial cells to detect microbes through pattern recognition re-
ceptors. Upon LPS stimulation of TLRs, the MYD88 protein is recruited, activating the NF-kB pathway, leading to production of antimicrobial proteins 
and proinflammatory cytokines. In a symbiotic gut, intestinal epithelial cells are desensitized by repeated exposure to LPS or are attenuated by LPS-
mediated downregulation of the IL1 receptor–associated kinase 1 (IRAK1), an activator of the NF-kB cascade. Exposure to LPS induces epithelial cells 
to secrete TGFβ, B-cell–activating factor of the TNF family (BAFF), and a proliferation-inducing ligand (APRIL), all of which promote the development 
of tolerogenic responses to the microbiota. CD103+ DCs support the development of Tregs to secrete IL10 and TGFβ, and together, they stimulate 
the production of commensal-specific IgA. Dysbiosis (right): increased intestinal exposure of diverse PAMPs, proinflammatory cytokines, apoptotic 
debris, and toxins leads to microbial dysbiosis and overgrowth of “pathobionts,” transformed symbiotic bacteria now under pathologic conditions. 
Pathobiont overgrowth leads to the loss of barrier integrity and a breach in the intestinal epithelial cell barrier. Translocation of bacteria and bacte-
rial components triggers the intestinal immune system through TLR activation, resulting in potentially harmful effector T-cell responses set to clear 
invading bacteria. Ultimately, the secretion of IL1 and IL6 from intestinal epithelial cells fuels a Th1 and Th17 response by DCs and macrophages and 
leads to higher levels of commensal-specific IgG by B cells.   
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inflammation are perceived to be a minimized febrile response, 
and correspondingly, this local response is only effective in the 
immediate region where it occurs (401). Since Coley’s passing, the 
field of tumor immunology has developed into a better founded 
and more sophisticated specialty, with investigators not only em-
ploying a variety of basic immunologic principles (e.g., antitumor 
cytokines, cytotoxic T cells, immunostimulatory antibodies, cell-
based vaccines) but pivotal insights into the dominance of tumoral 
immune suppression in blunting the effectiveness of any immuno-
therapy. Overcoming this historical source of failure in the efficacy 
of cancer immunotherapy is empowering this field anew today. 
There are more than a hundred chemotherapy drugs to treat 
many types of cancers. However, it is not fully understood the 
mechanism of some of these drugs. Cyclophosphamide is a clin-
ically important chemotherapeutic cancer drug that stimulates 
antitumor immune responses. Viaud and colleagues (410) dem-
onstrated that cyclophosphamide alters the composition of mi-
crobiota in the gut and induces the translocation of several Gram-
positive bacteria into mesenteric lymph nodes and spleen. In the 
lymphoid organs, the Gram-positive bacteria stimulated the gen-
eration of pathogenic Th17 (pTh17) cells and memory Th1 immune 
responses. Germ-free tumor-bearing mice or treated with antibi-
otics to kill Gram-positive bacteria showed a reduction in T-cell 
responses, and their tumors were resistant to cyclophosphamide. 
Adoptive transfer of pTh17 cells restored the antitumor efficacy of 
cyclophosphamide. Overall, the study suggested that the gut mi-
crobiota help shape the anticancer immune response. 
Turning the Tables: Using Engineered Microbes 
to Attack Cancer 
Over the past century, knowledge gained on how selective mi-
crobes either facilitate the growth of cancer or alternatively act as 
tumoricidal agents permits us open access to utilize this double-
edged sword to our advantage. Such interventions have already 
begun and span several modalities, including but not limited to 
the use of helper peptide sequences from bacterial subunits, bac-
terial toxin–fusion proteins, oncolytic viral vaccines, and, as recent 
studies elucidate, leveraging the metabolism of host flora to po-
tentiate immune modulators. 
Broadly defined, an immunotherapeutic is any modality that 
manipulates the immune system for enhanced therapeutic out-
come. These include nonspecific activation of the immune system 
with microbial components or cytokines, antigen-specific adoptive 
immunotherapy with antibodies or lymphocyte transfers, and ac-
tive immunotherapy by direct vaccination against tumor-specific 
proteins, or antigens. We traditionally regard vaccines as educa-
tors for the naïve immune system that are administered prophy-
lactically in anticipation of any infection. However, in the setting of 
aggressive cancers, the use of cellular vaccines to mount reactive 
immune responses is now being employed with promising results. 
A variety of cancer vaccines are currently under investigation, 
but perhaps the most widely investigated to date are (i) cellular 
vaccines composed of APC loaded with tumor antigen (411–414) 
and (ii) peptide vaccines (415, 416). Peptide vaccines are com-
prised of 8–25 amino acids that encompass an epitope, a recog-
nizable sequence coding for an antigen. The transient nature and 
low magnitude of responses in many cancer patients has eluci-
dated that tumors themselves are inherently proficient at down-
playing immune responses as well as escaping antigen recognition 
altogether. Thus, there is an urgent need for improving vaccine im-
munogenicity and for ensuring that cancer antigens are sufficiently 
immunogenic. To enhance peptide vaccine immunogenicity, these 
small peptides are often conjugated to a carrier protein, such as 
keyhole limpet hemocyanin (417, 418) and tetanus toxoid (419, 
420). These helper proteins enable recognition by and activation 
of the immune system with great potency and generate compli-
mentary bystander activation with cytokine release and maturation 
of effector cell phenotype. Peptide vaccines are appealing in can-
cer therapy because they are relatively easy to manufacture and 
store, and they do not require laborious preparations. Because of 
their “off-the-shelf” feature, repeated boosting for enhanced im-
mune activation also distinguishes peptide cancer vaccines as an 
expandable modality (421). 
Adoptive immunotherapy has also been utilized to eradicate 
established tumors (422). This process involves ex vivo activation 
of autologous immune cells, isolated from either peripheral blood 
or intratumoral lymphocytes (423, 424), into lymphocyte- activated 
killer cells. Lymphocyte-activated killer cells are generated by cul-
turing autologous peripheral lymphocytes with IL2, a vital growth 
cytokine for generating T cells and natural killer (NK) cells. These 
killer cells are then returned to the patient intratumorally or in-
travenously, where they become activated by host APCs and ex-
ert their tumoricidal effects. Using the knowledge we have gained 
from microbial components, NK cells have been potentiated by le-
veraging the cytolytic capacity of microbial diphtheria toxin. One 
study demonstrated that haploidentical NK cells for relapsed and 
refractory acute myeloid leukemia could be augmented and im-
proved with a lymphodepletive platform using diphtheria toxin 
conjugated to IL2. Using the immunotoxin IL2DT to deplete im-
munosuppressive Tregs, investigators appreciably improved rates 
of in vivo NK-cell expansion (10% vs. 27%) and AML 28-day re-
mission (53% vs. 21%; P = 0.02) compared with the cohort with-
out IL2DT (425). 
Oncolytic viruses represent another immunotherapy modal-
ity that has gained recent traction in the field of tumor immu-
nology. Use of these microbes was first based on early reports 
of spontaneous cancer remissions coincident with natural infec-
tion or upon the use of live attenuated vaccines (426). Since then, 
an improved understanding of the molecular basis for viral host 
cell tropism, cytotoxicity, and cell type specificity has opened up 
avenues for the very selective design of virally based anticancer 
strategies. To be efficacious and safe, an oncolytic virus must 
possess (i) an inherently low human pathogenic potential (i.e., 
the orphan reovirus; ref. 427); (ii) a veterinary pathogen with un-
known human pathogenicity (i.e., vesicular stomatitis virus; ref. 
428); or (iii) a human pathogen genetically engineered to selec-
tively kill cancerous cells without collateral cytotoxicity in nor-
mal cells (i.e., herpes simplex virus-1; ref. 429). One such group 
is utilizing a prototype nonpathogenic poliovirus recombinant, 
known as PVSRIPO. Poliovirus naturally targets the vast majority 
of ectodermal/ neuroectodermal cancers expressing its cellular 
receptor, CD155. Evidence from glioblastoma patients suggests 
that the CD155 receptor is ectopically upregulated on tumor 
cells. Preclinical studies have shown that treatment of glioma 
xenografts with intratumoral inoculation of PVS-RIPO produced 
rampant tumor cell death, potent host-mediated inflammatory 
reactions against infected tumors, and rapid tumor decline (430, 
431). The use of PVS-RIPO is now being evaluated in the phase 
I setting for recurrent glioblastoma (432). 
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As multiple studies are being carried out yearly, investigators 
continue to uncover key barriers to efficacy that further clarify our 
strategies. As with any antigen-specific immune response, several 
homeostatic mechanisms remain at play to prevent rampant dam-
age to the host or autoimmune toxicity. One of the most excit-
ing regulatory axes to be studied recently is that of programmed 
death (PD)-1/PD ligand-1 (PD-L1). PD-1 is a coinhibitory receptor 
that is inducibly expressed by T and B cells upon activation. Anti-
gen-specific T cells expressing the PD- 1 receptor will engage with 
either of its ligands, PD-L1 or PD-L2 expressed on APC, which elic-
its an inhibitory cascade and subsequent inhibition of TCR-induced 
cytokine production and proliferation (433). PDL-1 is expressed in 
several other cell types, including tumor cells and some epithe-
lial cells, lymphoid cells, and myeloid cells (434). Another axis in-
volved in regulating self-recognition is that of cytotoxic T lympho-
cyte antigen-4 (CTLA-4). Studies have demonstrated that tumor 
cells stimulate CTLA-4, promoting a cascade of inhibitory immune 
processes and ultimate T-cell inactivity against tumors themselves 
(435, 436). 
In cancer immunotherapy, mAbs against the immune check-
points CTLA-4, PD-1, and its ligand PD-L1 have demonstrated 
high activity in melanoma and other tumors (437). Ipilimumab, 
Figure 4. Gut microbiome directs the efficacy of immune checkpoint therapy. Both anti-CTLA-4 and anti-PD-L1 therapies rely on gut microbiota for 
efficacy in immune activation. Anti-PD-L1 therapy has been shown to rely on the preexistence of sufficient Bifidobacterium species, which are also 
thought to augment responses via PD-L1 binding on APCs, such as DCs and macrophages. Subsequent ligation results in the prevention of suppres-
sive signals to PD-1–expressing T cells. Similarly, anti-CTLA-4 indirectly alters the intestinal flora and enriches the Bacteroides species, possibly by 
promoting deterioration of the intestinal epithelial cell barrier via activation of local lymphocytes. These bacteria then promote the activation of DCs, 
which present tumor antigens to prime and maintain antitumor T-cell responses. Anti-CTLA-4 holds additional activation functions, including (i) pre-
venting CTLA-4 from blocking activation of the costimulatory molecule CD28 on T cells and (ii) blocking the immunosuppressive function of Tregs, 
which are required in the deactivation of immune responses against tumors.    
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an anti-CTLA-4 antibody, was the first approved “immune check-
point inhibitor.” Although the response rate with ipilimumab is 
low (less than 20% of patients have objective responses), many of 
those positive responses were associated with long-term survival 
(438), with similar results in the first- and second-line settings. 
Nivolumab and pembrolizumab, both anti-PD-1 inhibitors, have 
now also been approved for the treatment of melanoma, with re-
sponse rates of up to 40% and a demonstrated survival advantage 
in phase III trials (434). 
Strikingly, recent findings in preclinical models of cancer stress 
the importance of intact gut microbiota for effective immune 
checkpoint blockade. One recent study found that antitumor ef-
fects of CTLA-4 blockade depended on the presence of distinct 
Bacteroides species. In both mice and patients, T-cell responses 
specific for B. thetaiotaomicron or B. fragilis were associated with 
the efficacy of CTLA-4 blockade. Using antibiotic- treated as well 
as germ-free mice, tumors lacking these strains did not respond 
to CTLA blockade. This deficiency was rescued by B. fragilis ga-
vage, by immunization with B. fragilis polysaccharides, or by adop-
tive transfer of B. fragilis–specific T cells. Ultimately, fecal microbial 
transplantation from humans to mice confirmed that treatment of 
melanoma patients with antibodies against CTLA-4 favored the 
outgrowth of B. fragilis with anticancer properties (439). A differ-
ent preclinical study similarly elucidated that mice treated with gut 
commensals of Bifidobacterium displayed significantly improved 
suppression of melanoma growth in comparison with non- Bifi-
dobacterium–treated counterparts. These observed differences in 
spontaneous antitumor immunity were eliminated upon cohous-
ing or after fecal transfer, eluding to the importance of shared 
bacterial colonization. Furthermore, administration of the bacteria 
to Bifidobacterium-naïve mice with established melanoma signif-
icantly enhanced tumor-specific immunity and response to anti-
PD-L1 mAb therapy (440). Although the mechanisms from both 
these studies are not fully understood, they laid the foundation 
behind the requirement for an intact microbiome to enact antitu-
mor responses. One key observation from both these studies was 
that they employed subcutaneous tumor models, meaning that 
intestinal microbiota exerted antitumor immunity in a systemic 
fashion. Both studies relied on the presence of CD8+ T cells. Sec-
ond, both demonstrate that altered DC activation was a respon-
sible intermediate event between the presence of gut microbiota 
and provision of checkpoint inhibitors (Fig. 4). 
Conclusions 
It is humbling to consider how much biomedical research has been 
conducted since the molecular biology revolution of the past cen-
tury without appreciation of the importance of microbiomes in 
health and disease. Like all realms of biomedical investigation, 
the field of cancer research can no longer ignore the “other half” 
of the organism; it must become as familiar with the genetics, bi-
ology, physiology, and immunologic effects of host microorgan-
isms as with the hosts themselves. In considering sources of ex-
perimental irreproducibility in biomedical publications that have 
been suggested recently to be disturbingly high, it seems likely 
that natural variations in microbiome infections present in exper-
imental models and vivariums at different sites will provide one 
more challenge to the exquisitely difficult problem of how one de-
fines a “molecular mechanism” in disease. More focus on practical 
applications (sought by most funding organizations) along with 
empirical explorations once traditional to biology may offer two 
paths forward, as, to paraphrase the pragmatic American philoso-
pher Charles S. Peirce, “You know something if you can do some-
thing.” How the current obsession with molecular mechanism will 
change in the face of the challenge the microbiome poses to pre-
clinical research is unclear. Nevertheless, as the molecular biol-
ogy revolution continues to wash up on the shores of reduction-
ism this century, it will be impossible not to reembrace the roots 
of traditional biological thought, where ecology, evolution, and a 
focus on emergent principles in complex organisms can help re-
center the pursuit of new knowledge and its applications to im-
prove disease management and healthy lifespans.   
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